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1. Preface 
A work like this is never possible alone. I was supported by many people in my quest to 
understand the link between changed central pain processing and better management of 
chronic pain. It would not have been possible for me to realise my quest without the input, 
discussion, critique and multidisciplinary expertise which the collaborations that I was 
privileged to enter into over the years provided. In the following – non-exhaustive – list, I 
would like to pay tribute to some key persons who accompanied and supported me in this 
project. 
 
Geneva University Hospital in Switzerland was the place I started my pain research. Edömer 
Tassonyi, with whom I worked in the Anaesthesia Unit for Head Surgery gave me the 
enthusiastic support and advice essential for starting up my first research projects involving 
quantitative sensory testing (QST) after surgery. These projects would never have been 
realised without the tireless help of my colleagues at the department, such as Claude Senly 
and Dorothee Gaumann, in gathering data from the surgical patients.  
 
For one of the pioneering conferences on pain and surgery Edömer and I organised together 
in the early 1990s at Geneva, I invited Lars Arendt-Nielsen from the Centre for Sensor Motor 
Interaction (SMI) at Aalborg University, Denmark, to speak. A pioneer of the use of QST in 
experimental human pain research, he rapidly became a key long-term collaborator in my 
quest to apply QST for clinical pain research. Since then his enthusiasm, expertise and 
stamina have been a driving force for our many joint research projects, crucially contributing 
to the innovation and success of our studies. I have always enjoyed our close interactions 
over the years, and I fondly remember my time at the SMI in 2007 as visiting professor.  
 
A short time after getting to know Lars I encountered a colleague of his from Aalborg, 
Asbjørn Drewes, at a meeting on a new topic for me: visceral pain. His unique proficiency in 
– and passion for – the field of visceral pain and its study via QST and EEG proved irresistible. 
We also discovered another shared interest, good food, leading to many productive brain-
storming restaurant sessions together at conferences where we both happened to be 
speakers. Later on, we started to seriously collaborate on research into a further shared 
passion, pain in chronic pancreatitis, and this became another reason for regular trips to 
Denmark. The times I spent together with Asbjørn’s research team at Mech-Sense are 
memorable, as are the unique Danish PhD defences in which I was honored to be opponent.  
 
My long-lasting and close collaboration with my Danish friends is – and will continue to be – 
a great source of inspiration for me and my research into altered pain processing and its 
relation to pain diseases. 
 
Another person I invited to speak at a Geneva conference was Ben Crul, a pioneer in the 
development of clinical pain medicine in the Netherlands. Closely associated with the setting 
up of EuroPain, an early European group initiating and supporting collaborative pain 
research, his interest proved infectious and I was soon recruited to this cause, initially as 
board member, and later on to succeed Ben as president. Ben’s recruiting abilities did not 
end there, however, and at the beginning of the 21st century he persuaded me to join him at 
the Clinical Pain Unit of the Department of Anaesthesiology, Radboud University Medical 
Centre in Nijmegen, The Netherlands, to help set up a programme of pain research. He 
introduced me to the world of structured, professional, academic and multidisciplinary 
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clinical pain practice covering acute, oncological and chronic benign pain, while advising and 
lobbying enthusiastically regarding my pain research up to his retirement a few years later. I 
much appreciate the personal support Ben provided during my early years in Nijmegen, and 
for the energy and zeal he has continued to invest into the cause of developing clinical pain 
practice and research. 
 
Shortly after starting at Nijmegen, I was introduced to an energetic general surgeon, Harry 
van Goor, who – I was reliably informed – was also interested in pain. On getting to know 
Harry, I discovered that he was not only genuinely interested in pain, but that he was 
seriously interested in chronic pancreatitis. This combination proved difficult to resist, and I 
was soon involved in helping supervise the first of what was to become a line of PhDs 
investigating the field of chronic pancreatitis and pain. Fueled by Harry’s involvement in the 
Dutch Pancreatitis Group, we started up a systematic research programme to understand 
the impact which chronic pancreatitis has on central processing. This line was soon 
reinforced by Asbjørn and his team. Since then, our collaboration has gone on to publish 
cutting edge, internationally recognised innovation in our understanding of the mechanisms 
underlying chronic pain in the context of chronic pancreatitis. The close association with 
Harry continues to be one of the main engines driving my pain research and its 
development. 
 
When Ben Crul retired, he was succeeded by Kris Vissers, a specialist from Belgium in 
palliative care and pain medicine. Kris was preceded by a reputation as a talented medical 
administrator. Despite our different backgrounds, we discovered that we shared an zest for 
innovative medical research and its implementation in clinical practice with the goal of 
quantum-shifting its effectiveness for the patient. This discovery became the basis for an 
effective, long-term collaboration to transfer diagnostic methods revealing altered central 
processing in chronic pain from the laboratory to everyday clinical practice. Implementing a 
suitable QST system into clinical practice was key to this project. Thanks to Kris´ enthusiastic 
support, our Department has become the first worldwide to implement QST in regular, 
routine clinical pain practice in the form of the Nijmegen-Aalborg Screening QST (NASQ) 
presented in this thesis. With the support of Gert-Jan Scheffer, the Head of the Department 
of Anaesthesiology, the NASQ is now also finding its place in perioperative screening for risk 
of unfavourable pain outcomes after surgery. The complementary relationship Kris and I 
have developed will continue to be a bedrock of our ongoing research, development and 
clinical implementation programme to achieve pioneering QST-based systematic approaches 
to chronic pain management.  
 
An onerous and ambitious research programme such as the one presented in this thesis 
would not be possible without the talented and hard-working PhD students I have been 
privileged to supervise during my time at Radboud University Medical Centre. My warm and 
heartfelt thanks go out to André Wolff, Monique Steegers, Jan Oosterhof, Antoinette van 
Laarhoven, Hessel Buscher, Emanuel van den Broeke, Nicholas Chua, Stefan Bouwense and 
Hans Timmerman for their enthusiastic and dedicated contributions to our pain and QST 
research programme. 
 
Last – but certainly not least – I would like to thank my wife Elly for her constant, dedicated, 
enthusiastic and wise encouragement from the moment this project was born. You never 
doubted the necessity and usefulness of implementing QST to radically transform clinical 
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pain practice. Your proof-reading was always of the highest standard. Even in times of 
discouragement you never ceased to have faith in my ability to crack this nut! With much 
pleasure I remember our many stimulating discussions, arguing the pros and cons of the 
research and its presentation – and (always your strong point) how to make it impact reality 
by improving the daily life of the patient. Without your patient and persuasive backing this 
thesis would not yet have seen the light of day! Thank you for being my opposite in the 
process of conceiving and writing this project, for your unwavering belief in my vision of 
better pain patient management, and your ongoing support in matters of daily living during 
the period of putting the thesis to paper. 
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2. Introduction 
Pain, both acute and chronic, is an unpleasant but common part of life. In its acute form, it 
carries an important warning message to the person suffering from it, namely to change his 
behaviour to avoid further harm and damage. However, in some patients, pain does not go 
away after the acute episode, and persists, losing its useful warning message connected to 
the avoidance of tissue damage. Ultimately it becomes chronic pain, a disease of pain 
processing in its own right. 
 
How this transition from a useful adaptive physiological response to a maladaptive 
pathological process occurs, the nature of this maladaptive response, and how it progresses 
over time has been a central question of pain research for the last few decades. My 
particular interest in this field – and the subject of my research for the last fifteen years – 
has been, firstly, how to effectively diagnose such chronic pain in patients, particularly its 
genesis and its progression, and, secondly, by the clinical implementation of such diagnostics 
to lay the foundation for successful chronic pain management in daily practice. 
 
2.1. Defining the Problem 
2.1.1. Acute Pain 
Acute pain is the pain accompanying some form of tissue damage or trauma, and is usually 
considered to last a few days after the event. A much-studied model of acute pain is that 
accompanying surgery. Typically surgery is accompanied by severe acute pain in the first few 
days after surgery, with pain being spontaneous, ongoing or evoked by movement 
(coughing, mobilisation). The pain is usually most severe the first and second days after 
surgery, gradually decreasing thereafter to usually disappear – at least in its spontaneous or 
ongoing form – at the end of the first postoperative week 1,2. 
 
In a recent study of major surgical interventions 43%, 27% and 16% of patients experienced 
significant spontaneous or ongoing pain (VAS≥40 mm) on postoperative days 1, 2 and 3, 
respectively 2. For any type of pain – ongoing or evoked – the respective incidences of 
significant pain (VAS≥40 mm) for postoperative days 1, 2 and 3 were 88%, 81% and 72% 2. In 
reviewing the literature, major postoperative pain appears to be present in between 30 – 
70% of surgical patients, with at least 20% achieving inadequate pain relief overall 3,4. 
Unfortunately, it has to be noted that acute postoperative pain management has not 
improved over the last decade despite a variety of concerted attempts at improvement 
during this period 4,5. 
 
2.1.2. Persistent Postoperative Pain 
Pain persisting beyond three to five days after surgery is only now being recognised as a 
negative outcome in its own right. Thirty to fifty percent of patients undergoing amputation, 
mastectomy, thoracotomy or sternotomy still show persistent pain 3-6 months after surgery, 
with 5 – 10% of these reporting severe pain 6-8. Even “minor” interventions such as inguinal 
herniorrhaphy are associated with significant incidences of postoperative persistent pain 9. 
Approx. one third of inguinal herniorrhaphy patients still complain of moderate or severe 
pain one week after surgery, with the figure at one month and one year being 10% and 10-
15%, respectively 9-11. If we combine the many operations performed each year (NL: more 
than 1.5 million) with the acute and persistent pain incidences just cited, pain after surgery 
has a major and significant medical and societal impact. It should be noted that once 
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persistent pain becomes chronic pain, a maximum of one third of the patients will benefit 
from presently available therapeutic options 6,8. 
 
2.1.3. Chronic Pain 
Established chronic pain is defined by the International Association for the Study of Pain 
(IASP) as pain present for longer than six months. Chronic pain, not only of surgical but also 
of non-surgical origin, is a major medical and societal problem in the Western world. Chronic 
widespread musculoskeletal pain, for example, is reported in ca. 10% of the general 
population 12. In 1995, total Dutch costs for low back pain, the commonest form of chronic 
pain, were estimated at some EUR 3.7 billion per year, equivalent to almost 2% of the gross 
national product and a per capita cost per year of EUR 240 13. In a large Dutch general 
population study, almost half the respondents had low back pain in the past year, and some 
40% reported that the episode was continuously present or had lasted more than 12 weeks 
14. 62% of low back pain sufferers still have pain 12 months later, with acute recurrence 
within one year of an episode in up to 73%, and a lifetime recurrence rate of up to 85% 15-17. 
Over 90% of low back pain costs are indirect and related to work and invalidity, with a small 
group of patients (10-25%) with recurrent, long-lasting and severe low back pain causing 
75% of total costs 13,18,19. Thus limited treatment success and major societal impact define 
presently practised conservative as well as the interventional low back pain management 
options 17,19-23. Again it should be noted that also in the field of chronic pain, there is an 
ample body of research identifying the limited impact of current standard therapeutic 
approaches. 
 
2.1.4. Summary 
In summary, chronic pain and the transition from acute to chronic pain continues to have a 
major societal impact regarding suffering and cost. Despite major and concerted efforts in 
the last two decades at achieving effective management of this problem through scientific 
and organisational advances, little real impression has been made by present therapeutic 
approaches on the prevention and treatment of chronic pain. Thus chronic pain must be 
regarded as a frequent, clinically relevant and undesirable societal and medical problem in 
urgent need of new, effective management approaches. 
 
2.2. The Key: Pain and Neuroplasticity 
In contrast to the ongoing practical problems in achieving a clinical therapeutic impact on 
pain, fundamental research regarding pain and its underlying mechanisms has been more 
successful. Thus the last two decades have seen crucial and significant improvements in our 
understanding of the mechanisms underlying nociception and pain. A key insight has been 
that nervous system processing of nociception and pain is not hard-wired, and that the gain 
of the nervous system typically changes as a result of noxious sensory inputs. Acute 
nociception typically initially results in increased pain sensitivity (hyperalgesia) affecting the 
peripheral and central nervous system 24-26. Initially, it sensitises the peripheral nervous 
system via excitatory substance release from damaged tissues and nerves. The resulting 
nociceptive barrage to spinal cord, brainstem and brain in turn excites the central nervous 
system (central sensitisation), further increasing sensitivity. 
 
2.2.1. Excitatory Neuroplasticity 
In basic animal models, excitatory neuroplasticity (i.e. “sensitisation”) moves from activation 
(acute, transient, activity-dependent) via modulation (sub-acute, slower, but still reversible 
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functional changes) through to modification (chronic structural and architectural alterations) 
25. Activation involves use-dependent augmentation of transduction (peripheral nociceptors, 
autosensitisation) and transmission (central processing, wind-up) and should be considered 
a rapidly reversible physiological process 25. Modulation expresses itself in peripheral and 
central sensitisation, mainly due to phosphorylation of neuronal receptors and ionophores; 
it is a more slowly reversible process with early pathological connotations 25. Modification is 
considered the basis of chronic, pathological pain, and entails altered regulation and cell 
connectivity together with cell death, particularly affecting inhibitory systems 25. 
 
2.2.2. Inhibitory Neuroplasticity 
For intact organisms, these excitatory changes quickly elicit counteracting inhibitory 
responses 27. Such inhibitory responses, an integral part of the complex modulation 
excitatory nociceptive transmission normally undergoes from peripheral to central in the 
nervous system 28,29, can be spinal or supraspinal. The latter, also termed descending 
inhibition, operates via multiple tonic and phasic systems, originates in medulla and 
midbrain, and is closely related to parallel descending facilitatory systems 28-31. The ability to 
produce an inhibitory response (e.g. diffuse noxious inhibitory controls, DNIC) is now 
considered to be an important prognostic factor for human development of chronic pain, 
and its absence may contribute to increase the initial excitatory responses described above 
32,33. The quality of inhibitory responses may carry important prognostic information 
regarding susceptibility to chronic pain 33-35. 
 
2.2.3. Clinical Reality of Neuroplasticity 
The reality of the changes in sensory processing accompanying human acute pain, e.g. due 
to surgery, is now well demonstrated, both by my research (I, II, IV, VIII, IX, X) and by other 
groups 36-42. Sensitised pain processing and pro-nociceptive pain modulation have further 
been demonstrated to accompany and characterise many human chronic pain diseases 43, 
including low back pain (III) 44,45, fibromyalgia 46-48, osteoarthritis 32, CRPS (VII) 49 and visceral 
pain (VI,VII, X) 50. Furthermore, in large cross-sectional population studies, it has been 
demonstrated that more pro-nociceptive pain processing (e.g. poorer DNIC) is also 
associated with a greater risk of chronic pain in general 33,35. 
 
2.2.4. Summary 
In summary, the key finding of pain research of the last decades has been that nociceptive 
input results in altered pain processing, and that such alterations in pain processing are also 
seen in the context of developing and established chronic pain. From these findings, it 
appears logical to conclude that making such alterations in pain processing visible in patients 
in the clinical context – and then targeting these therapeutically – may be the key to 
achieving effective management approaches to the hitherto largely intractable problem of 
chronic pain and its development. 
 
2.3. The Tool: Quantitative Sensory Processing (QST) 
Over the last couple of decades quantitative sensory testing (QST), also termed 
psychophysical testing, has emerged as a potential tool for monitoring and diagnosing pain 
processing and its alterations in patients 51-54. This technique is based on the application of 
defined stimuli to the patient under standardized conditions, and then asking the patient to 
rate the stimulus regarding its experienced intensity. The use of multiple stimuli with 
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differing intensities makes it possible to construct stimulus-response relationships 
characterizing the state of the patient’s pain processing (Figure 1). 
 
Figure 1: Typical stimulus-response curve obtained from plotting responses obtained from multiple stimuli 
during quantitative sensory testing. 
 
This technique has the advantage of permitting assessment of the entire pain stimulus-
response curve from subthreshold to suprathreshold input. The major disadvantage of this 
approach is that it is time-consuming, and requires that the subject be well trained in rating 
pain stimuli accurately and reliably 55. 
 
Figure 2: Ramping quantitative sensory testing involving application of stimuli of increasing intensity. Here, 
multiple thresholds can be determined, e.g. sensation or pain detection threshold or pain tolerance threshold. 
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In clinical practice, the procedure is often simplified by determining only one point on the 
stimulus-response curve, namely a threshold for the transition to pain (the pain threshold) 
or “intolerable” pain (the pain tolerance threshold). Thresholds are typically determined 
using a simple ramping procedure, which is quick, but subject to anticipation effects and 
reaction time (Figure 2, above). Up-and-down techniques such as the method of limits are 
more accurate, with the disadvantage of being more time-consuming (Figure 3, below) 
52,55,56. Thresholds are a frequently used monoparameter for clinical research into pain 
processing as it is quick and easy to train patients in their use. The limitations of such a 
monoparameter, particularly if it does not involve suprathreshold stimulation, must, 
however, be kept in mind when interpreting it as a measure of pain processing. 
 
Figure 3: Method of limits approach, involving successive stimuli above and below threshold gradually closing 
down on the pain threshold. 
 
The information derived from QST about pain processing can be increased by stimulation of 
different tissues (e.g. skin, muscle, viscera) in a variety of anatomical locations (topography, 
e.g. to distinguish between segmental and generalized hyperalgesia). Further information 
can be obtained by altering the nature of the stimulus (e.g. thermal, mechanical, electrical, 
chemical), or by investigating the effect of a conditioning stimulus (e.g. a cold pressor task 
via ice water bucket immersion) on pain processing by applying test stimulation before, 
during and after conditioning stimulation. A typical example of the latter is the diffuse 
noxious inhibitory controls (DNIC) paradigm 32,57-61, also called a conditioned pain 
modulation (CPM) paradigm 62-66. The CPM (or DNIC) paradigm (Figure 4, below) is robust 
and relatively insensitive to minor details of experimental setup, and makes it possible to 
visualize the effectiveness of phasic descending inhibitory mechanisms – or the pro- vs. 
antinociceptive balance – in a given patient or patient population 33,34,60,61,66. 
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Figure 4: Conditioned pain modulation (CPM) paradigm for testing descending modulation of pain inputs. The 
effect of a tonic painful conditioning stimulus (CS) is revealed by test stimuli applied before, during and after 
conditioning stimulation. Test stimuli are quantified either by determining pain experience (e.g. pain VAS) or 
pain thresholds (e.g. pressure pain threshold (PPT) in kPa). Graph on right shows PPTs before, during and after 
conditioning stimulus with either inhibitory (inhibit) or facilitatory (facilitate) modulation. 
 
In summary, QST techniques are potentially useful in diagnosing a variety of aspects of the 
pain processing state of patients. QST can be either static (test stimuli only) or dynamic (test 
and conditioning stimuli), with the former providing information about basal pain sensitivity, 
while the latter provides information about pain modulation. The results can be interpreted 
either at a given time in reference to normal value data (e.g. 67,68), or in the context of 
disease progression via multiple measures in time. We have demonstrated the latter 
approach is particularly valuable in the perioperative context, as many patients are pain-free 
before surgery and can therefore serve as their own normal controls (I, II, VI, XIII). 
 
2.4. The Solution: A Systematic Approach to Altered Pain Processing (SATAPP) 
Why have we been so unsuccessful in improving outcomes of human pain diseases despite 
the impressive advances in animal experimental understanding of pain mechanisms 
summarised above? I consider three related reasons to underlie this problem, which will be 
discussed in the following sections. 
 
2.4.1. Translation Difficulties 
The first reason has to do with the basal scientific knowledge which our practice of pain 
medicine is based upon, and the difficulties of translating the results of animal research to 
human clinical practice. As already discussed, basic animal research has certainly been 
successful in unravelling the mechanisms underlying various aspects of pain – in animals. 
However, difficulties arise when one attempts to extrapolate findings from animal research 
directly to the human situation. A major reason is the different endpoints which are used in 
animals and patient pain research. Resolution of this problem requires a determined effort 
to use the same endpoints reflecting similar mechanisms in animal and human research. One 
candidate for achieving this goal is the use of measures reflecting alterations in pain 
processing common to both animal and humans. It should be noted that this approach can 
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be complicated by the differences in the anatomy and physiology of pain processing in 
animals vs. humans, particularly regarding more rostral neuraxial (e.g. cortical) aspects of 
pain processing important in chronic pain and its development 69,70. 
 
The practical consequences of translational problems are illustrated by the pre-emptive 
analgesia debate 71-74, and the ongoing difficulties in the use of animal models for the 
development of analgesic drugs for clinical human use 75. In both cases, predictions 
regarding clinical treatment approaches based on pain mechanisms elucidated in animal 
models fail to be accurate in the human clinical context, resulting in lack of success of the 
derived therapeutic concepts. The main reason for this failure was that different endpoints 
were used in animals and humans, namely altered pain processing in animals, versus altered 
pain experience in humans 27. 
 
2.4.2. Symptoms vs. Altered Pain Processing 
The second reason is that current clinical pain treatment continues to be essentially 
symptom-based, palliating symptoms instead of targeting underlying alterations in pain 
processing 76. As detailed above, we have come to the point of being forced to accept that 
there is a limit to what can be achieved therapeutically with our present empirical, 
symptom-based approach to pain, particularly regarding chronic pain and its development 
8,17,19-23,27. This finding is only reinforced by recent unsuccessful attempts to derive insights 
into possible underlying mechanisms from a systematised approach to clinical physical signs 
of pain disorders 77. In fact, a recent fMRI study of chronic low back pain patients comments 
that changes in brain pain processing explain 70-80% of pain variance, as opposed to the 20-
25% explained by traditional biopsychosocial factors upon which symptom-based treatment 
is based 21,78. What is thus necessary is a major shift of emphasis away from symptoms of 
pain experience and towards the alterations in pain processing underlying pain disorders. 
 
2.4.3. Documenting Altered Pain Processing in Human Pain Patients 
This necessary shift in emphasis brings us to the third reason, namely that the work of 
systematically and comprehensively understanding the pathophysiological processes and 
mechanisms active on a systems level in the nervous system of actual human pain patients 
has barely begun. These necessary insights into diseased pain processing mechanisms can 
never be generated with adequate certainty or detail from animal or human healthy 
volunteer research: they must be collected from actual human pain patients in the clinical 
context. Although this approach may appear onerous, the advantage of it is that, once 
realised, it also permits rapid clinical application of the knowledge and technology so 
generated. Systematic application of the knowledge concerning altered pain processing 
provided by such clinical research is the basis for achieving effective treatment for chronic 
pain and its development orientated towards altered pain processing – rather than based on 
pain symptoms. Key in this context is the implementation in everyday clinical practice of the 
diagnostic technologies developed in the course of research targeting altered pain 
processing. 
 
2.4.4. The Challenge: Achieving a Systematic Approach to Altered Pain Processing in Patients 
In summary, it is time to institute a fundamental paradigm shift in clinical pain medicine. This 
shift requires that we leave behind old empirical symptom-based methods and move 
towards a new, systematic approach to altered pain processing (SATAPP) in pain disorders. 
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Achieving this paradigm shifting approach requires concerted research and development 
activities in three areas, namely: 
 
1) development of diagnostic techniques informing about altered pain processing in the 
human clinical context, 
2) use of these diagnostic techniques to define the alterations in pain processing 
typically accompanying human pain disorders, and 
3) identification and development of a comprehensive therapeutic armamentarium 
targeting various aspects of altered pain processing. 
 
Based upon research and development in these three areas, we can achieve the 
development and validation of a comprehensive systematic approach to altered pain 
processing based on QST (SATAPP.QST) as the foundation for successful diagnostics and 
therapeutics of human pain disorders. 
 
2.5. Aim of the Present Review: Implementing SATAPP.QST in Pain Medicine 
The aim of the present review is to provide a basis for the just-described paradigm shift in 
pain medicine away from symptom-based management towards a systematic approach to 
altered pain processing in pain diseases. Based on the research I have done over the last 
fifteen years, the review will concentrate on demonstrating the following: 
 
1) Quantitative sensory testing (QST) represents a valid method of diagnostics for 
altered pain processing now suitable for implementation into routine clinical 
practice; 
2) Implementation of diagnostics targeting altered pain processing using QST provides 
real clinical benefit in the diagnostics, prognostics and monitoring of chronic pain 
disorders and their progression; 
3) First examples of pain management paradigms effectively targeting altered pain 
processing are now available, without going into pharmacological details of specific 
drug regimes, which lie beyond the scope of the present work; and 
4) Based on 1-3, achieving and implementing a systematic approach to altered pain 
processing based on QST (SATAPP.QST) regarding pain diagnostics and therapeutics 
in clinical pain practice is now feasible. 
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3. SATAPP.QST 
3.1. Clinical Application of SATAPP in Pain Disorders 
To achieve the paradigm shift towards a systematic approach to altered pain processing 
(SATAPP) in pain medicine discussed above, I consider it essential to provide answers to the 
following four key diagnostic questions regarding pain disorders in the clinical context: 
 
3.1.1. What is the peripheral source of nociceptive input? 
We assume that most chronic pain disorders start off with a nociceptive source. Knowledge 
of this source and its nature enables us to try to deal therapeutically with the source, or to 
try deafferenting it with drugs or invasive procedures. Furthermore, this information permits 
identification of particularly aggressive types of nociceptive input (e.g. visceral pain). 
 
3.1.2. Is nociceptive transmission from periphery to centre altered? 
Nerve damage is a common reason for altered nociceptive transmission from periphery to 
centre. Diagnosis of nerve damage is particularly important because it is a strong 
predisposing factor to aggressive alterations in central pain processing. Furthermore, 
damaged nerves can in themselves be an additional source of aggressive nociceptive input. 
 
3.1.3. Is central nociceptive processing altered? 
Answering this question is central to achieving SATAPP, and quantitative sensory testing 
(QST) is the key to diagnosing altered central nociceptive processing. Two main classes of 
altered central pain processing are described in the literature, necessitating the following 
two basic questions: 
 
Firstly: has central sensitivity to pain altered? The presence and persistence of central 
sensitisation has significant prognostic and therapeutic consequences, as previously 
discussed. More extensive spread of central sensitisation can indicate more advanced or 
serious pain disease. Furthermore, the presence of central sensitisation makes measures 
aiming at peripheral deafferentation less effective, and requires the use of own specific and 
targeted therapeutic approaches. 
 
Secondly: what is the state of descending central pain modulation? A pro-nociceptive shift 
in central pain modulation may not only carry negative prognostic implications concerning 
development or progression of chronic pain, it also again requires specific and targeted 
treatment strategies. 
 
3.1.4. Is altered central nociceptive processing still driven by peripheral nociceptive input? 
Normally (some) peripheral nociceptive drive is necessary to maintain (some of the) 
alterations in central pain processing. There is early evidence that under certain conditions, 
altered central processing might become autonomous, i.e. no longer dependent on 
peripheral nociceptive drive. If this is so, this might not only have prognostic connotations, 
but might also mean that peripheral deafferenting measures will be ineffective, making 
specific treatment dealing with altered central pain processing mandatory. 
 
The paradigm for our systematic approach to altered pain processing (SATAPP) is 
summarised below (Figure 5). 
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Figure 5: Diagnostic SATAPP paradigm for diagnosing pain disorders. 
 
3.2. Diagnostic Needs for SATAPP: QST 
As already mentioned, it is now well-recognised that nociception results in altered nervous 
system sensory processing. Affecting the peripheral and central nervous system, this 
expresses itself both as alterations in basal pain sensitivity as well as changes in pain 
modulation. Typically, the initial response is increased pain sensitivity (hyperalgesia), 
generally rapidly followed by inhibitory modulatory responses 24-26. 
 
In clinical practice it is impossible to objectively and reliably diagnose altered pain processing 
based on symptoms or physical examination alone. There is therefore a real and pressing 
need for diagnostic technologies permitting the quantification of pain processing in the 
human clinical context. Quantitative sensory testing (QST) is such a technology. Also termed 
psychophysical testing, QST is a methodology for systematically quantifying alterations in 
nervous system sensory function. By formally documenting stimulus-response relationships 
for pain processing, QST makes visible changes in pain sensitivity and modulation as the 
basis of a SATAPP in the diagnosis of pain diseases. 
 
QST was initially introduced for neurological sensory diagnosis. In this field, QST is now well-
accepted and validated, particularly for the diagnosis of small fibre neuropathy, where it is 
considered the diagnostic gold standard 51-56. Later on, QST was introduced into pain 
medicine, initially to help diagnose neuropathic pain, but now increasingly for the specific 
purpose of diagnosing the changes in pain processing accompanying nociception and pain. 
Today QST can be regarded as an established and validated technique, not only specifically 
for neuropathic pain 53,54,67,68,79, but also for general pain medicine 32,44,45,52,80-85. 
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3.3. QST Methods for SATAPP 
Quantitative sensory testing (QST) has been developed and validated over the last couple of 
decades as a clinical method in the context of pain disorders for monitoring and diagnosing 
pain processing, its alterations and its modulation 51-55. QST can be defined as the 
determination of stimulus-response relations for nervous system sensory processing under 
standardised conditions 51,52,55. Its aim in pain medicine is to formally define the relationships 
between a stimulus (how strong is the applied stimulus?) and the response (how painful 
does it feel?), and how these relationships are modulated endogenously and exogenously. 
 
3.3.1. Static QST 
Static QST provides information regarding the subject’s basal pain sensitivity. This technique 
is based on the application of defined, usually phasic stimuli to the patient under 
standardized conditions. The patient is then asked to rate the stimulus regarding its 
experienced intensity. The use of multiple stimuli with differing intensities makes it possible 
to construct stimulus-response relationships characterizing the state of the patient’s basal 
pain sensitivity. Increased pain sensitivity, for example, can thus be objectively quantified by 
the leftward shift it produces (vs. baseline) of the pain stimulus dose-response curve (Figure 
6, below) 55. 
 
Figure 6: Quantitative sensory testing in pain medicine is based on the construction of a stimulus-response  
(S-R) curve as illustrated in this figure. The normal S-R curve is shifted to the left by the nociceptive input 
accompanying pain, causing both hyperalgesia and allodynia. A pain threshold is a defined point on the S-R 
curve and can thus be used a monoparameter to make visible changes in pain processing such as hyperalgesia 
or allodynia. Due to the non-linear nature of the S-R relationship, the monoparameter “threshold” will not 
reliably reflect all aspects of pain processing, e.g. the behaviour of suprathreshold stimulation. 
 
This procedure is often simplified by determining only one point on the stimulus-response 
curve, namely a threshold for the transition to pain (the pain threshold) or “intolerable” pain 
(the pain tolerance threshold). Thresholds are a frequently used monoparameter for clinical 
research into pain processing as it is quick and easy to train patients in their use. The 
limitations of such a monoparameter, particularly if it does not involve suprathreshold 
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stimulation, must, however, be taken intio account when interpreting it as a measure of pain 
processing. 
 
Combining different stimulation approaches permits more complete quantification of 
nociceptive system state under normal and pathophysiological conditions 86,87. The painful 
test stimuli can be varied by type, location and tissue stimulated. For “physiological” stimuli 
(e.g., pressure, temperature, chemical) peripheral nociceptors participate in pain processing. 
In contrast, electrical stimuli largely bypass nociceptors, reflecting mainly neuronal aspects 
of nociceptive processing 88,89. This contrast can be used to provide clues about the state of 
the peripheral nociceptors and nerves involved in transducing nociceptive inputs. 
 
Stimulation in a variety of anatomical locations (topography) permits conclusions to be 
drawn about the origin of the altered pain processing within the nervous system. QST 
measured close to and distant from surgery can, e.g., differentiate between generalised (e.g. 
supraspinal) and segmental (e.g. spinal) changes in pain processing (I). Combination with 
different types of stimulation allows further conclusions to be drawn. Examples include 
secondary or segmental mechanical hyperalgesia indicative of spinal central sensitisation, or 
thermal hyperalgesia localised to the site of tissue damage with peripheral sensitisation. 
 
Finally, further information can be obtained by stimulating different tissues (e.g. skin, 
muscle, viscera). Skin – a superficial somatic structure particularly susceptible to sensory 
modulation – is the most frequently stimulated tissue for QST due to its easy accessibility. 
Altered pain sensitivity in structures deep to the skin is more difficult to access directly. Such 
sensitivity may be indirectly studied using cutaneous or muscle projections (e.g. referred 
areas of viscera) 44,86. Direct QST of such structures is more invasive and onerous, but can 
provide additional useful information about altered pain processing in deep structures auch 
as muscle 44,45 or viscera (e.g. oesophagus 86). 
 
Combining all of these data will permit the construction of characteristic patterns of altered 
pain sensitivity associated with various types and stages of pain disorders. At present, QST 
involving mechanical and electrical stimulation of the skin or mechanical (pressure) 
stimulation of deeper tissues (muscle, bone) are considered the most reliable and feasible,, 
and are thus the most frequently used in clinical practice 51,52,55,56,90,91. 
 
3.3.2. Dynamic QST 
QST may be used to test the effect of a conditioning stimulus on the just discussed pain 
stimulus-response curve. Conditioning may take the form of repeating the (phasic) test 
stimulus in time or space (Figure 7, below). Such summation informs on mechanisms, e.g. 
windup, spinal central sensitisation, potentially of relevance to chronic pain and its 
development 92. 
DSc (Aalborg) OWS 
Page 19 of 76 
 
Figure 7: Wind-up paradigm showing effects of temporal summation. Graph on the right shows pain numeric 
rating score (NRS) for each stimulus; last stimulus of series is more painful than the first, quantified as temporal 
summation ratio (TSR=NRS for 10
th
 stimulus/1
st
 stimulus). 
 
Alternatively, the effects of a variety of (usually tonic and heterotopic) conditioning stimuli 
on pain processing can be investigated by applying test stimulation before, during and after 
conditioning stimulation. A typical example is the conditioned pain modulation (CPM) 
paradigm, also called the diffuse noxious inhibitory controls (DNIC) paradigm 57-62. CPM is 
induced via a noxious tonic conditioning stimulus (e.g. cold pressor task) applied remotely 
from a conditioned test (heterotopic, phasic) pain stimulus, typically resulting in raised pain 
thresholds and decreased pain perception for the test stimulus 32,60,66,93. The CPM paradigm 
(already presented previously in Figure 4) is robust and relatively insensitive to minor details 
of experimental setup, and makes it possible to visualize the size of descending inhibitory or 
facilitatory controls – or to gain insight into the pro- vs. antinociceptive balance – in a given 
patient or patient population 30,31,33,34,59-61,66,75,94-96. A further example is to use high 
frequency electric cutaneous stimulation as a conditioning stimulus to study the ease of 
inducing central sensitisation via long-term potentiation 97-101. 
 
3.3.3. QST Interpretation 
The results of QST measurements are typically interpreted either in reference to normal 
values or in reference to the patients’ own values before disease or intervention. Normal 
value databases (e.g. as generated by the German Neuropathic Pain Network 67,68), are 
based on QST results obtained in large populations of healthy volunteers of both genders 
and multiple age ranges, and are scarce due to the considerable resources necessary to 
generate them. A typical example where a patient can provide his own reference values is in 
the perioperative context, as many patients are pain-free before surgery and can therefore 
serve as their own controls 102 (I, II, VI, XIII). Some groups propagate using the side of the 
body unaffected by pain to provide control values 67,68, but this remains problematic in view 
of the possibility of spread of altered pain processing to the other side, either due to spread 
across the spinal cord midline or activation of supraspinal mechanisms. 
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3.4. Clinical Implementation: The Nijmegen-Aalborg Screening QST (NASQ) Paradigm 
As already mentioned above (Figure 5), there are four basic diagnostic questions which form 
the foundation for a systematic approach to altered pain processing in pain disorders. QST 
provides results relevant to all four questions. 
 
However question three, i.e. regarding altered central pain processing, is the key question to 
answer. This is, firstly, because the presence of altered central processing has serious 
prognostic implications for the pain disorder under consideration, and secondly, because its 
presence is often poorly responsive to traditional pain treatments targeting nociceptive 
input, and requires specific therapeutic measures targeting central pain processing. 
Moreover, answering question three also provides results relevant to question two (nerve 
damage can be diagnosed using neurological QST and is typically associated with aggressive 
changes in central pain processing) and question four (concerning the relationship between 
altered central processing and peripheral nociceptive input). 
 
A large variety of QST paradigms, both static and dynamic, are available involving different 
forms of stimulation and different ways of quantifying pain responses. Based on our clinical 
research experience, we designed a standard screening QST paradigm, the Nijmegen-
Aalborg Screening QST (NASQ), suitable for implementation into clinical practice. My 
choices regarding details of the NASQ paradigm were based on 1) what elements of altered 
pain processing one wants to address and which forms of QST are suitable for this, 2) the 
scientific evidence that the chosen QST paradigm usefully reflects this aspect of altered pain 
processing in clinical practice, and 3) practicability and validity for everyday clinical use. 
 
My considerations regarding which forms of altered central pain processing NASQ should 
first target for clinical use, and the forms of QST suitable for diagnosing these, will be 
addressed in the following sections of the present chapter. More detailed evidence for the 
effectiveness of NASQ paradigms in diagnosing altered pain processing in clinical pain 
practice will be supplied in subsequent chapters dealing with perioperative and chronic pain. 
 
Regarding practicability and validity, our NASQ paradigm characterised below generally lasts 
about 30 minutes and was well-accepted by patients. Rigid standardisation of the protocols, 
restriction of measurements to one or two trained personnel, careful initial instruction and 
training of subjects, and measurement in a quiet secluded room ensured good 
reproducibility (within 20%) and thus reliability of QST measures. 
 
3.4.1. NASQ and Altered Central Pain Processing: Central Sensitisation 
Central sensitisation, both spinal and supraspinal, plays a key role in developing and 
established chronic pain conditions – a role much more important than peripheral 
sensitisation. In this context, two types of spread of central sensitisation appears to be 
particularly linked to development and progression of chronic pain diseases, namely 1) 
spread of central sensitisation rostrally up the neuraxis, i.e. towards supraspinal or cortical 
structures, and 2) spread to heterotopic structures or tissues, e.g. from skin to deeper 
tissues such as muscles. A further reason for detecting central sensitisation is therapeutic: 
there is accumulating evidence that central sensitisation, once established, responds 
increasingly poorly to “classic” analgesic measures such as opioid analgesia or peripheral 
nerve blockade, thus requiring own specific and targeted treatment approaches 103. 
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Thus the first alteration of pain processing which I considered the NASQ paradigm should 
target is the presence and spread of central sensitisation. A suitable QST paradigm for the 
detection of central sensitisation and spread should fulfill the following conditions: 
 
1) The ability to detect mechanical hyperalgesia. This is crucial because the secondary 
hyperalgesia surrounding injured tissue, which is generally considered a definitive 
manifestation of central sensitisation, is mechanical in nature. 
2) The ability to assess spread of central sensitisation. This involves homotopic spread, 
e.g. to skin distant from the nociceptive source, as well as heterotopic spread, e.g. to 
muscle, a very important tissue involved in many pain diseases. 
3) The ability to quantify pain sensitivity not only at but also above pain threshold. This 
is important because most clinically relevant pain processing is suprathreshold. 
 
To fulfil these conditions, the NASQ paradigm contains the following elements: 
 
1) Pressure pain thresholds. These mechanical thresholds detect mechanical 
hyperalgesia of deep tissues such as muscle, thus also permitting assessemtn of 
heterotopic spread of central sensitisation, and are considered clinically robust and 
reliable 67,68,104. 
2) Electrical detection, pain detection and pain tolerance thresholds. These permit the 
assessment of skin hyperalgesia, and thus central sensitisation, at and above pain 
threshold and in comparison with non-nociceptive sensory processing. The ability to 
stimulate multiple nerve fibre populations and to bypass peripheral nociceptors (and 
their sensitisation) provides valuable additional insight into more neuronal aspects of 
pain processing, despite the alleged “unphysiological” nature of the stimulus. 
3) Pain thresholds at multiple sites. Multisite measurements allow differentiation 
between segmental (spinal) vs. generalised (supraspinal) central sensitisation, and 
the quantification of neuraxial spread of central sensitisation. The minimum of sites 
is two, one close and one distant from the nociceptive source. 
 
To achieve these ends in clinical practice, I applied simple QST paradigms to determine 
thresholds via ramping electrical and mechanical stimulation. For mechanical stimulation, I 
used a simple commercially available electronic pressure algometer. Pressure algometry 
stimulates mainly deeper structures such as muscle, with only a minor contribution from 
skin processing if used in the classical vertical mode (vs. the pinching mode) 89,105,106. For 
electrical stimulation we used a simple constant-current device delivering electric tetanic 
stimuli. Transcutaneous electric stimulation stimulates only superficial cutaneous and 
subcutaneous structures. It bypasses nociceptors by stimulating cutaneous nerve endings 
directly, thus providing information on more central aspects of skin pain processing 107,108. To 
explore different aspects of nociceptive and non-nociceptive sensory processing, we 
determined electric sensation (non-nociceptive processing), pain detection and pain 
tolerance (suprathreshold pain processing) thresholds. Electrical and pressure algometry 
stimulation were chosen for their ease of use and controllability, as well as for their proven 
ability to detect both inhibitory and excitatory changes in pain processing 32,46,105,107,109. Both 
devices proved reliable and safe in routine clinical use. 
 
The NASQ includes thresholds at multiple sites. For surgical patients, this involved measuring 
– as a minimum – at one site close to surgical incision and one distant from it. This permits 
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differentiation of generalised (reflecting supraspinal processing) and localised or segmental 
(reflecting peripheral or spinal processing) changes in pain processing, thus allowing 
identification of rostral neuraxial spread of altered pain processing in time (I,VI). For the 
chronic pain patients, we again compared, as a minimum, healthy and affected sites, once 
more allowing differentiation between segmental and generalised changes in pain 
processing and their neuraxial spread (I, VI, VIII, IX, XIII, XV). Figure 8 (below) summarises the 
part of the NASQ paradigm I developed to diagnose spreading central sensitisation, which 
takes about 20 minutes to perform. 
 
 
Figure 8: NASQ part I to detect spreading central sensitisation 
 
3.4.2. NASQ and Altered Central Pain Processing: Descending Modulation 
I had previously mentioned that the central nervous system responds to initial nociceptive 
input and excitation by generating counteracting inhibition of both spinal and supraspinal 
origin to depress both noxious spinal inputs and subsequent central sensitisation. In this 
case, it is generally supraspinal descending modulation which is dominant. There is good 
evidence, which will be discussed in more detail in subsequent sections, that descending 
supraspinal modulation, particularly the net balance between pro- and antinociceptive 
forces, plays a key role in the genesis, progression and prognosis of chronic pain diseases. 
 
In this context a pronociceptive shift of descending pain modulation not only facilitates the 
entry and ascent of nociceptive signals into the central nervous system, it also favours the 
rostral spread of central sensitisation up the neuraxis to supraspinal structures, thus 
ultimately producing the mix of altered nociceptive and non-nociceptive supratentorial 
processing so characteristic of chronic pain patients. Again there are further, therapeutic 
reasons for specifically diagnosing altered central pain modulation. Thus there are not only 
first indications that altered pain modulation responds to different therapeutic manoeuvres 
DSc (Aalborg) OWS 
Page 23 of 76 
than central sensitisation, but also that certain treatments may be less effective in the 
presence of pronociceptive descending pain modulation. 
 
Thus the second alteration of pain processing which I considered the NASQ paradigm should 
target is the balance between pro- and antinociceptive descending modulation. It should be 
noted that the presence of descending facilitation is likely to encourage the genesis and 
spread of central sensitisation. To diagnose descending modulation I used a conditioned pain 
modulation (CPM) paradigm eliciting a phasic brainstem descending inhibitory control 
response, diffuse noxious inhibitory controls (DNIC), containing the following elements: 
 
1) An aversive painful, tonic, heterotopic conditioning stimulus. Heterotopy between 
test and conditioning stimuli ensures maximum supraspinal processing contribution 
to the modulatory response; the other conditions ensure that we are dealing with 
clinically relevant modulation of pain processing. 
2) Phasic, heterotopic test stimuli. The reason for heterotopy has already been 
explained, phasic test stimuli are chosen to minimise the effect which test 
stimulation has on pain processing. The test stimuli are applied at least before and 
just after conditioning stimulation to quantify its modulatory effect. 
3) Multimodal test stimuli. This is because we cannot necessarily expect descending 
modulation of different test stimuli to be the same, e.g. for skin vs. muscle. 
4) Test stimulation distant and extrasegmental to conditioning site. This ensures that 
the modulation elicited applies to the entire body, as would be expected for 
descending controls of supraspinal origin, e.g. DNIC. 
 
I chose the cold pressor task as the tonic painful conditioning stimulus as it is extremely 
aversive, technically simple to produce and well-validated in the literature 110-113. Based on 
the literature, maximum immersion time was limited to 180 seconds, and pain scores pre- 
and post-immersion documented to assure standardisation of the cold pressor task 112. The 
cold pressor task was further selected because it is heterotypic to the test stimuli chosen 
and also delivers insight into tonic pain sensitivity of the subject via the hand withdrawal 
latency 112,113. For test stimulation before and after cold pressor task conditioning we used 
the same multimodal electric and mechanical test stimuli described above for simple 
sensitivity testing. Conditioning stimulation was applied to the upper extremity. Test 
stimulation was carried out on the upper thigh to quantify the distant extrasegmental CPM 
response, with the response being defined as the percentage change of electrical and 
pressure pain tolerance threshold after vs. before conditioning (XIII). Figure 9 (below) 
summarises the part of the NASQ paradigm I developed to diagnose shifts in descending 
nociceptive modulation, which can be either in the direction of inhibition or in the direction 
of facilitation. This part of the NASQ paradigm takes about 10 minutes to perform. 
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Figure 9: NASQ part II using Conditioned Pain Modulation (CPM) paradigm developed to detect pro-or anti-
nociceptive shifts in descending pain modulation. IWB = ice water bucket. 
 
3.5. Summary: NASQ Paradigm for SATAPP.QST 
Quantitative sensory testing to diagnose alterations in pain sensitivity and modulation is 
central to achieving rational and effective a systematic approach to altered pain processing 
in pain disorders. As indicated above, the capacity of QST to diagnose central sensitisation 
and altered central pain modulation makes it key in answering the questions about altered 
central pain processing. Thus the diagnosis of central sensitisation and altered pain 
modulation is central in the design of the Nijmegen-Aalborg Screening QST (NASQ) 
paradigm. The ability of QST to help diagnose peripheral sensitisation and nerve damage can 
also be useful in diagnosing peripheral sources of nociceptive input and disorders of 
nociceptive transmission. In combination with methods to achieve temporary 
deafferentation of peripheral nociceptive input, QST can help quantify the relationship 
between the latter and altered central pain processing. In the following chapters covering 
specific aspects of perioperative and chronic pain, I will provide more detail regarding the 
role of NASQ in the clinical implementation of a systematic approach to altered pain 
processing (SATAPP.QST) in pain medicine. 
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4. SATAPP.QST for Perioperative Practice 
4.1. Pain and Surgery 
4.1.1. Pain after Surgery: An Ongoing Problem 
Post-surgical pain remains a significant and challenging problem. Around 40% of patients 
experience major acute postoperative pain, about 25% report inadequate pain relief 3. This 
situation has not improved over the last 10-15 years despite concerted efforts including the 
widespread introduction of acute pain services and associated practice guidelines 1-3,5. For 
chronic postoperative pain the situation is even less satisfactory, and its significance has only 
started being appreciated.4,6-8,114 The literature now becoming available reports incidences 
of chronic pain of up to 75% for major operations such as amputation or thoracotomy (Table 
1) 8. Even common, relatively minor procedures such as inguinal hernia repair are associated 
with chronic pain prevalences of up to 30% 6,8,10,11,115-117. It appears that 10 to 50% of 
patients complain of chronic pain after surgery, and that this pain is severe, impairs quality 
of life and is thus significant in 2 to 10% of postoperative patients 8. Furthermore about a 
quarter of patients attending a chronic pain outpatient clinic attribute their pain to previous 
surgery 114. In summary, pain, particularly chronic pain, is a frequent, clinically relevant and 
undesirable outcome after surgery that is in urgent need of new, effective medical 
management approaches. The present section provides a review of the relevant literature 
regarding the relevance of altered sensory processing to the problem of chronic pain after 
surgery. 
 
 
Table 1: Estimated incidence of chronic pain and disability after selected surgical procedures. Reproduced from 
reference 
8
 with permission. 
 
4.1.2. Clinical Risk Factors for Chronic Pain after Surgery and Altered Sensory Processing 
What links clinical risk factors associated with higher prevalences of chronic postoperative 
pain to altered pain processing? Answering this question is important because, once these 
links are understood, they may be used to develop and test hypotheses regarding the 
mechanisms underlying development of, and increased vulnerability to, chronic pain after 
surgery. In clinical practice, lacking awareness and understanding of underlying alterations in 
pain processing results impedes the implementation of effective management approaches to 
surgical pain based on altered pain processing. This in turn helps explain the fact that 
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incidences of acute and chronic postoperative pain continue to be high despite rigorous 
medical and organizational efforts towards its reduction. 
 
The literature to date has identified a number of risk factors associated with higher 
prevalences of chronic pain after surgery. These can be grouped into patient-related, 
surgery-related, psychosocial and socio-environmental aspects. Prominent risk factors in the 
literature include female gender, younger age, the presence of pre- and postoperative pain, 
type and extent of surgery, and nerve damage 8,10,11. All of these factors can be linked to 
altered pain processing. Thus lower age, consistently associated with higher incidences of 
chronic postoperative pain, may be associated with a more vigorous neuroplastic response, 
while gender-dependent differences in pain modulation are now well-described in the 
literature (XI, XII) 6,8,10,118-120. Surgery-related risk factors linked to increased incidences of 
chronic pain after surgery, including more preoperative pain, more pain and higher analgesia 
consumption in the early postoperative period, more extensive surgery, and nerve damage 
have increased pain sensitivity in common, in that these factors can all be either expressions 
of hyperalgesia (more preoperative or postoperative pain, more postoperative analgesia 
consumption), or a cause thereof (nerve damage, more extensive surgery) 6,8,10,27,118-120. 
Other factors associated with higher risk of chronic pain after surgery, e.g. altered genetic 
status via polymorphisms in relevant genes, or the psychosocial factor of catastrophizing 
status, are now increasingly discussed in the literature and also linked to altered pain 
processing 121-138. 
 
4.1.3. Nociception and Central Nervous System Processing in the Surgical Context 
It is generally accepted that nociceptive input such as surgery alters pain processing by the 
nervous system 8,24-27,125,139,140. This alteration is initially excitatory, usually rapidly followed 
by inhibitory modulation. In the following sections I briefly summarise the relevance of 
altered central nervous system processing in the perioperative context to a systematic 
approach to altered pain processing. 
 
4.1.3.1 Altered Nociceptive Transmission: Nerve Damage 
I would like to emphasize that the consequences of nociceptive input are more aggressive in 
the presence of nerve damage than in other contexts such as inflammation. Clinically highly 
associated with more chronic pain after surgery 8, nociception in the context of nerve 
damage is also linked to more central sensitization, greater loss of inhibitory controls, and 
increased descending facilitation 141,142 (Figure 10, below). Such shifts to a pro-nociceptive 
state not only favour the development of hyperalgesia, they also risk favouring the rostral 
spread of central sensitisation and the development of changes in central pain processing so 
characteristic of chronic pain patients. 
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Figure 10: Effects of increasing nerve damage on central processing of afferent nociceptive input. Inflammation 
alone results in strong descending inhibitory modulation (inh) of primary afferent nociceptive input. Formalin, 
which irritates nerves, results in less inhibitory (inh) and more facilitatory (fac) modulation. Nerve damage 
(neuropathy) elicits almost exclusively facilitatory (fac) descending modulation of primary afferent nociceptive 
input. PAG=peri-aqueductal grey, RVM=rostroventral medulla, LC=locus cereolus. Modified after 
141
. 
 
4.1.3.2. Altered Central Pain Processing: Central Sensitization 
Both peripheral and central pain processing by the nervous system can be sensitised by 
nociceptive input, a process clinically manifest as hyperalgesia 25-27,139. Central sensitization is 
more relevant to clinical pain conditions, and can be the result of 1) enhanced neuronal 
membrane excitability, 2) increased synaptic efficacy (e.g. via long-term potentiation) and 3) 
altered modulation in the sense of both disinhibition and facilitation 26,139,143-146. Persistence 
and progression of central sensitization as a result of ongoing nociceptive input is considered 
a central process in the development of chronic pain in the basic animal research literature 
24-26,125,139. 
 
With ongoing nociceptive input, central sensitization traverses three increasingly longer-
lasting, irreversible and pathological stages, namely activation (transient, activity-
dependent), modulation (slower but still reversible functional changes) and modification 
(chronic structural and architectural alterations) 25. Activation involves use-dependent 
augmentation of transduction and transmission (e.g. wind-up) and is a rapidly reversible 
physiological process 25. Modulation is a more slowly reversible process with early 
pathological connotations. It is mainly due to phosphorylation of neuronal receptors and 
ionophores (e.g. the N-methyl D-aspartate (NMDA) receptor and associated calcium 
ionophore) 25. Modification includes altered regulation and cell connectivity together with 
cell death, and is generally viewed as the basis of chronic, pathological pain. Typically it 
entails modified gene transcription together with loss of inhibition, both functionally and via 
death of inhibitory neuron populations 25. 
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4.1.3.3. Altered Central Pain Processing: Central Modulation 
As previously pointed out, nociceptive input elicits counteracting modulatory responses by 
the central nervous system. Segmental spinal inhibitory controls, the so-called “spinal gate” 
of Melzack and Wall 147, represent a first line of defense. Most prominent are the descending 
inhibitory controls targeting the spinal dorsal horn and thus the first pain pathway synapse, 
using pathways descending from the brain, particularly from the brainstem 148. These 
systems are selective for nociceptive processing, and can be both inhibitory and facilitatory. 
They are thus decisive for the balance of nociceptive transmission, ultimately determining 
whether pain processing is in a pro- or antinociceptive state 148. 
 
Descending inhibitory control can be broadly divided into three systems:  
The first is the tonic midline peri-aqueductal grey – rostro-ventral medulla (PAG-RVM) 
system (of which the locus coeruleus may be considered a part). Its ON- and OFF cells project 
downwards to the spinal dorsal horn, and facilitate or inhibit nociceptive input, respectively 
30,31,141,148,149. The PAG-RVM system is subject to a variety of supraspinal and cortical 
modulating inputs 148, and has been demonstrated to control pain sensitivity in a variety of 
animal models for chronic pain states including arthritis, visceral and neuropathic pain 
94,142,148,150. 
A second, phasic system carries the name “diffuse noxious inhibitory controls” (DNIC). It is 
based on a spino-bulbo-spinal loop involving the dorsal reticular nucleus of the medulla 
(DRN)57,58,60,61,66,151-153. DNIC can be elicited in animal and humans by applying a local noxious 
conditioning stimulus which then results in a generalized decrease in pain transmission (the 
CPM (conditioned pain modulation) paradigm62,66), as evidenced by lower evoked pain 
responses or higher pain thresholds to test stimulation distant from the site of conditioning 
stimulation 59-61. The descending inhibition of DNIC affects on spinal dorsal horn wide 
dynamic range (WDR) neurons of the entire neuraxis, and is considered to not only to be 
involved in endogenous analgesia but also whole body enteroception, e.g. by improving 
signal-to-noise ratios for nociceptive input 70. 
Supratentorial top-down controls comprise the third system. They are believed to be the 
CNS substrate for the influence of cognitive and affective factors on pain and pain 
processing, e.g. placebo and nocebo effects 31,141,142,148-150,154-159. Here higher structures 
including prefrontal cortex, cingulate cortex, amygdala and hypothalamus have widespread 
connections with the PAG-RVM system, forming the basis of a variety of central positive and 
negative feedback loops activated by noxious sensory input 148,154-156,160. 
 
4.1.3.4. Altered Central Pain Processing: Dependence on Peripheral Nociceptive Input 
There are indications that after aggressive and/or long-lasting ongoing nociceptive input the 
ensuing alterations to central pain processing become progressively less dependent on the 
initiating afferent nociceptive input 161,162. If this is so, then autonomous central processing 
independent of peripheral nociceptive input could represent the end stage of the process of 
chronic pain development. This topic is dealt with in more detail in the next chapter. 
 
4.2. Synopsis of Own Contributions 
Eight of my articles included in this review deal with the perioperative situation. In these 
articles I define the problem of perioperative pain, document the time course of 
perioperative alterations in pain processing, and investigate the perioperative factors 
influencing postoperative pain outcomes. 
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4.2.1. Defining the problem 
In a large survey of perioperative and emergency room analgesia in Switzerland (IV) I 
attempted to define the problems as perceived by the doctors practicing in this area. 
Encouragingly, the majority of the doctors questioned were convinced of the key 
contribution which effective perioperative pain management makes to better long-term pain 
outcomes after surgery. However, I was able to identify serious problems and concerns 
concentrated in two main areas, namely education and organisation. Thus less than half the 
respondents said they had undergone —or were undergoing – structured or accredited pain 
education, and less than a third participated in regular educational meetings with the goal of 
providing ongoing training and providing feedback and troubleshooting for pain 
management problems in everyday perioperative practice. Regarding organisation, less than 
a third of respondents regularly determined pain scores in the perioperative context, only 
some 15% performed regular analysis of pain outcomes in the context of a quality assurance 
programme, and barely 10% had standard treatment plans (algorithms) in place upon which 
to base postoperative analgesic management. None of the respondents formally assessed 
sensory processing in the perioperative context. 
 
We further studied the influence of nerve damage on chronic pain incidence after breast 
cancer surgery (XI). It is well-known that axillary lymph node dissection is associated with 
surgical damage to large nerves traversing the axilla. In a large retrospective survey of 
patients having undergone breast cancer surgery we documented that concomitant axillary 
lymph node dissection doubled the prevalence of chronic pain from 23% to 51%. Moreover, 
axillary lymph node dissection also interacted with both postoperative chemo- and 
radiotherapy to further increase the risk of chronic pain. These results strongly support a 
major role of nerve damage in the genesis of chronic pain after surgical interventions. 
 
Thoracic surgery is associated with a high incidence of chronic pain 8. This high incidence is 
again considered to be the result of nerve damage, incurred as a result of rib retraction 
during thoracotomy. In a large retrospective study of thoracic surgery, I was able to confirm 
the high prevalence of chronic pain (XII). However comparison of chronic pain prevalences 
for open thoracotomy ( 40%) and for thoracoscopic procedures (47%) suggests that nerve 
damage may not be the only factor explaining high incidences of persisting pain after 
surgery, as thoracoscopy does not involve rib retraction, significantly reducing the likelihood 
of nerve damage. This finding is supported by the results from the use in my study of a 
validated screening questionnaire for neuropathic pain in these patients, which showed that 
only 23% of these patients had definite signs of neuropathic pain, while 47% showed no 
signs of neuropathic pain. Thus it is likely that other sources of poorly modulated nociceptive 
input, e.g. visceral nociception accompanying thoracic surgery, also play a significant role in 
increasing risk of persisting or chronic pain after surgery. 
 
4.2.2. Time course of altered sensory processing after surgery 
Few other studies have systematically investigated the time course or topography of altered 
pain processing after surgery. My research has produced the only published documentation 
to date of the long-term time course of altered postoperative pain processing, involving 
multiple QST measurements from one hour up to six months after surgery. This is the first 
time long-term monitoring of altered pain processing using a multimodal QST paradigm such 
as NASQ has been shown to be feasible in the clinical context. 
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Furthermore, my studies are the only ones to have assessed heterotopic spread of altered 
central processing by measuring both electrical thresholds, reflecting skin sensitivity 
(without nociceptor contribution) and mechanical pressure pain thresholds, reflecting deep 
tissue (e.g. muscle) sensitivity (I,II, VI, XIII). My studies are further unique in having measured 
thresholds at multiple sites to differentiate peri-incisional (i.e. secondary) hyperalgesia from 
spreading changes in pain processing expressed as generalised hyperalgesia. In particular, 
our studies appear to be the only ones to systematically investigate the phenomenon of 
generalised hyperalgesia. This is important as peri-incisional changes will reflect mainly 
altered spinal processing, while generalised changes will tend to reflect supraspinal 
mechanisms. The distinction is key because in comparison to spinal sensitisation, supraspinal 
spread of central sensitisation, firstly, has more pathological connotations regarding chronic 
pain development, secondly, is more difficult to reverse, and thirdly, has more extensive 
effects on other aspects of CNS processing 24-27,30,31,33,35,43,142,149,150,163,164. 
 
My studies show that during the first 24 postoperative hours, inhibitory changes as revealed 
by electric skin pain thresholds predominate. The fact that inhibition affected all sensory 
modalities, including non-nociceptive ones, tends to speak against morphine effects, as 
opioids mainly affect tonic pain stimuli corresponding to pain tolerance thresholds and C-
fibre transmission, leaving A-beta fibre mediated non-nociceptive sensory transmission 
unchanged 165,166. Thus we suggest this acute, inhibition is likely due to tonic descending 
inhibitory controls, e.g. from the PAG-RVM system 148, acting on spinal wide dynamic range 
neurons 167. This view is supported by the generalised and acute nature of the inhibition and 
its effects on both nociceptive and non-nociceptive sensory modalities 152,167,168. The level 
adaptation theory suggests that pain thresholds change due to reference point resetting, but 
is disqualified by the parallel changes in non-nociceptive processing seen in our studies 169. 
 
From day one to the end of the first postoperative week, excitatory changes can become 
visible, with peri-incisional and spreading/generalised hyperalgesia increasing considerably 
from postoperative day 1 to 5 (I, II, VI, XIII). This increase in hyperalgesia occurs parallel to a 
reduction of pain scores and analgesia consumption, again underlining the general lack of 
correlation between clinical pain measures and QST measures found in our – and others’ – 
research. The results suggest that spread of central sensitisation up the neuraxis to 
supraspinal structures can occur quite early – i.e. the first few postoperative days – and that 
it is not well reflected in clinical pain measures. Of note is that – under some circumstances – 
the presence of substantial descending inhibitory controls during the first 24 hours is not 
enough to prevent this subsequent spread from occurring. Certainly nerve damage seems to 
play an important role in this context, as my studies show spreading/generalised 
hyperalgesia on postoperative day five in back surgery patients (who often show nerve 
damage), but not in hysterectomy patients (who generally do not have nerve damage). 
 
Other studies have described peri-incisional secondary mechanical hyperalgesia from 24 
hours up to 7 days after surgery 37-42, congruent with our results using electrical stimulation 
(I, VI, XIII). Only two of the quoted studies determined pressure pain thresholds 37,39, the 
others quantified hyperalgesia by mapping the area of punctuate hyperalgesia (i.e. 
secondary hyperalgesia) around surgical incision 38,40-42. Using mapping after abdominal 
surgery, one group found peri-incisional hyperalgesia areas to increase from postoperative 
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day 1 to 3 40-42. These results are compatible with our findings, particularly in view of the 
strong correlation we found between peri-incisional and generalised hyperalgesia (I, VI, XIII). 
 
My research is unique in having extended the period of QST monitoring of altered sensory 
processing to six months after surgery (XIII). We have shown that, for major abdominal 
surgery, patients without chronic pain at six months do not in general show significant 
postoperative hyperalgesia of the skin or muscle during their six month postoperative 
course. In contrast, patients with chronic pain six months postoperatively demonstrate 
persistence of both skin and muscle hyperalgesia – from one day up to six months 
postoperatively. Both pain experience (i.e. VAS for pain) and pain processing (hyperalgesia 
spread) postoperatively were affected by the inhibitory effectiveness of preoperative pain 
modulation. Thus greater preoperative inhibition of skin nociceptive inputs reduced 
postoperative persistent pain VAS, while greater preoperative inhibition of muscle/deep 
tissue nociceptive inputs reduced postoperative spreading deep tissue hyperalgesia. 
 
Remarkably, postoperative hyperalgesia from day one to three months postoperatively in 
the group with chronic pain was not accompanied by higher pain VAS; increased VAS were 
only seen at six months, again demonstrating the only weak link between subjective 
measures of pain experience and measures of altered pain processing. These results suggest 
that the development of chronic pain after surgery is linked to the persistence and rostral 
spread of neuraxial central sensitisation, and that this process can start early, i.e. days after 
surgery. Furthermore, it would appear that the changes in supratentorial pain processing 
which underlie the altered subjective pain experience of chronic pain takes some time, i.e. 
months after surgery, to develop. This concept is summarised in Figure 11, below. 
 
 
Figure 11: This schematic illustrates the concept of progressive neuraxial spread of central sensitisation 
(progression numbered by black-filled circles) following ongoing nociceptive inputs due to the tissue and nerve 
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damage (consequences numbered via unfilled circles) of surgery. Note that each stage of rostral spread of 
central sensitisation is subject to descending modulation. 
 
4.2.3. Preoperative factors and postoperative pain outcomes 
A number of studies have found preoperative pain ratings evoked by suprathreshold tonic 
thermal stimuli to predict early postoperative pain scores – but without studying effects on 
postoperative hyperalgesia 110,137,170,171. My studies are the only ones to systematically 
investigate the preoperative prediction of early postoperative hyperalgesia using QST. Thus I 
found preoperative pain tolerance thresholds in an area distant from back surgery to be a 
strong factor predicting generalised hyperalgesia from 24 hours to 5 days postoperatively. 
Here low preoperative pain tolerance thresholds (i.e. high sensitivity to phasic pain 
stimulation) were found to correlate with less generalised hyperalgesia postoperatively. In 
the one study where we examined this phenomenon in more detail (VI), we further found 
this relationship to be disrupted by pre-emptive opioid supplementation, suggesting that 
such supplementation prevented the state change driving the relationship between 
preoperative pain thresholds and subsequent generalised hyperalgesia. This result is in line 
with the previously discussed concept of preemptive analgesia by opioids and the 
prevention of the central nervous system state change of central sensitisation 25,71,172-175. 
 
The relationship between low preoperative pain tolerance thresholds and decreased early 
postoperative hyperalgesia may appear counterintuitive at first. Because we did not 
measure CPM/DNIC in this early study, we can only speculate that perhaps a lower (phasic) 
pain threshold in a person with a healthy pain processing system leaves more room for 
dynamic inhibitory processes than if the threshold is higher. This is supported by recent 
studies indicating a ceiling effect for the DNIC response elicited when using the CPM 
paradigm 60. If true, this would associate higher thresholds with decreased ability to produce 
DNIC or other inhibitory modulation. However, the relationship between CPM responses and 
basal pain thresholds has not been reported to date for healthy persons. Alternatively, a 
higher threshold might simply be associated with more tonic inhibition to lose. Clearly more 
specific research targeting this area is necessary. Our studies do suggest (particularly study 
VI), however, that it should now be possible to estimate a cut-off point for preoperative pain 
tolerance thresholds above which the risk of developing generalised early postoperative 
hyperalgesia is significantly present, and that this cut-off point will vary with the surgical 
procedure and type of analgesic supplementation of anaesthesia. 
 
In another study (study V), I demonstrated that the presence of low back pain is associated 
with more generalised hyperalgesia, in keeping with the results from other studies 
45,78,176,177. In the context of back pain patients undergoing back surgery (I, VI), I also found 
that the presence and degree of preoperative low back pain influenced the incidence – but 
not the degree – of generalised hyperalgesia in the first postoperative week 178. The effect of 
preoperative pain was large, doubling the incidence of significant generalised hyperalgesia in 
the first postoperative week. Taking these two results together, we suggest that it is the 
preoperative hyperalgesia accompanying preoperative back pain which contributes to the 
increased vulnerability of these patients to generalised hyperalgesia in the early 
postoperative period after back surgery. These considerations would also help explain the 
poor outcomes of back surgery for chronic low back pain 15,16,19,20,22,23,179,180. 
 
In the human pain research literature, impaired inhibitory pain modulation ability (e.g. 
CPM/DNIC response) has been connected to risk or presence of chronic pain 32-34,46,181,182. 
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Furthermore, impaired inhibitory controls are also linked to the presence of hyperalgesia, a 
process in which descending facilitation also plays an important role 31-33,43,183. It would thus 
appear logical to postulate that weaker preoperative inhibitory modulatory responses (e.g. 
measured via CPM/DNIC paradigm) might increase the risk of developing generalised 
hyperalgesia and thus persistent and chronic pain after an acute nociceptive episode such as 
surgery. Both of these suggestions are supported by our study on abdominal surgery and 
chronic pain, which not only links chronic pain to poorer skin CPM responses, but also links 
heterotopic spread of hyperalgesia to poorer deep tissue CPM responses (XIII). Further 
support is provided by another study where poor preoperative skin CPM responses were 
associated with more chronic pain after thoracotomy 95. 
 
In summary, our studies have identified three factors, i.e. 1) high basal pain tolerance 
thresholds, 2) generalised hyperalgesia due to chronic pain disorders as well as 3) poor 
inhibitory descending pain modulation as significant preoperative predictors of 
postoperative risk of spreading hyperalgesia and its subsequent persistence. Spreading and 
persisting hyperalgesia is in turn linked to poor longer-term pain outcomes. 
 
4.2.4. Intra- and early postoperative factors and postoperative pain outcomes 
In my studies, effective antinociception started before surgery reduced postoperative 
spreading hyperalgesia. Thus opioid analgesic supplementation of anaesthesia started 
preoperatively improved inhibitory responses for the first 24 postoperative hours after back 
surgery for all sensory modalities. Furthermore, such pre-emptive analgesia was 
subsequently able to prevent significant postoperative hyperalgesia from developing (i.e. 
reductions in pain tolerance thresholds in the first postoperative week (I, II, VI)). However, 
opioids started postoperatively and continued for 24 hours were not able to subsequently 
prevent such spreading hyperalgesia (I, VI). Taken together, these findings suggest that 
opioids given before nociceptive surgical input starts are able to sufficiently inhibit 
nociception (perhaps together with acute endogenous inhibitory responses) to prevent 
subsequent spinal central sensitisation and its progression up the neuraxis to become visible 
as spreading hyperalgesia. Conversely, opioids started after surgery are not sufficiently 
potent with regard to depressing established central sensitisation 103 to prevent its 
subsequent neuraxial spread and expression as spreading or generalised hyperalgesia. These 
results are in keeping with the neurophysiological evidence from animal experiments for the 
phenomenon of pre-emptive analgesia 25,72,175,184, and represent the first true clinical proof 
of its reality. To our knowledge, only one other study has formally demonstrated the 
effectiveness of pre-emptive parenteral opioids using QST to date 185. 
 
Another group has studied long-term effects (up to 1 year postoperatively) regarding pain 
outcomes of antihyperalgesic treatment using intravenous ketamine infusion combined with 
continuous epidural analgesia in abdominal surgery patients. This study showed decreased 
areas of peri-incisional hyperalgesia up to three days postoperatively and less chronic pain 
up to six months after surgery using a perioperative intravenous infusion of ketamine 40. This 
study did not, however, investigate prediction of postoperative hyperalgesia or pain based 
on preoperative QST findings (e.g. via pain thresholds or CPM/DNIC paradigm). These results 
are in agreement with other studies of postoperative pain processing after perioperative use 
of ketamine 37,38,40,41,186,187, and are congruent with the generally beneficial effects of 
ketamine on postoperative pain outcomes 186,188-192. The group found similar results for 
intrathecal clonidine, suggesting that both ketamine and clonidine may be effective in 
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reducing acute and chronic rostral neuraxial spread of central sensitisation in the context of 
chronic pain development. 
 
Further re-analysis of my studies 178 (I, II, VI) would suggest that the incidences of significant 
spreading hyperalgesia in the first postoperative week (i.e. pain threshold reduction greater 
than 25% vs. preoperatively) were generally greater for back surgery than hysterectomy (24 
hours postoperatively: 24% vs. 3%; 5 days postoperatively: 67% vs. 40%; respectively). 
However, the hysterectomy patients had no pain preoperatively, and on comparing back 
patients without preoperative pain with hysterectomy patients, similar incidences of 
generalised hyperalgesia are found (24 hours: 8% vs. 3%; 5 days: 44% vs. 40%; respectively). 
We have found no other studies formally investigating the effect of different types of 
surgery on postoperative pain processing to date. 
 
In summary, my studies in conjunction with others suggest that effective antinociception, 
antihyperalgesia and type of surgery influence postoperative spread and persistence of 
hyperalgesia, and thus contribute to better long-term postoperative pain outcomes. 
 
4.2.5. Late postoperative factors and postoperative pain outcomes 
Our research is the first to link the development of chronic pain after surgery to the 
persistence and spread of hyperalgesia postoperatively. My results show that patients 
developing chronic pain six months after surgery show persistent and spreading hyperalgesia 
at one, three and six months after surgery, particularly of skin, but also of deep tissues such 
as muscle. Based on these data, which are compatible with the neuraxial persistence and 
spread of central sensitisation, we would suggest that the presence of heterotopic spreading 
hyperalgesia beyond the first week or so after surgery indicates an increased risk for the 
later development of chronic pain. Our data further suggest that alterations in purely 
nociceptive processing, which tend to involve more caudal neuraxial central sensitisation, 
predate the changes in pain experience typical of chronic pain, with its characteristic 
additional alterations in non-nociceptive processing (e.g. cognitive, affective) and effects on 
more rostral aspects of nociceptive processing. Clearly, further research will be necessary, 
firstly to confirm the innovative hypotheses generated by our research, and secondly, to 
validate resulting sensitive biomarkers documenting the risk of developing chronic pain. 
 
4.3. Synthesis of Current Knowledge: Altered Pain Processing Before and After Surgery 
The following paragraphs summarise and systematize what is now known – also as based on 
the contributions of my perioperative research – about perioperative alterations in pain 
processing as the basis for realising SATAPP.QST in the perioperative period. 
 
4.3.1. Preoperative Period 
Hyperalgesia is increasingly documented in patients preoperatively. Surgery for chronic low 
back pain is linked to poor chronic pain outcomes 17,20,22,179,180,193-196. In the context of back 
surgery for intervertebral disc prolapse, patients with low back pain preoperatively were 
significantly hyperalgesic just before surgery compared to those without pain preoperatively 
(V). Those patients with preoperative pain also had a significantly higher incidence of 
generalized hyperalgesia at the end of the first postoperative week (Figure 12, below) 178. 
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Figure 12: Effects of presence or absence of preoperative pain on incidence (in percent) of postoperative 
hyperalgesia greater than 25% (vertical axis) in back surgery patients. Horizontal axis gives hours (H) or days (D) 
postoperatively. Modified after reference 
178
. 
 
Similarly, patients awaiting hip replacement surgery for chronic pain due to osteoarthritis, 
demonstrate not only generalized hyperalgesia, but also impaired inhibitory controls during 
CPM paradigm 32. Interestingly, hyperalgesia and poor inhibitory controls reverted to normal 
in the pain-free state six months after hip replacement surgery 32. This suggests that in these 
patients, central alterations in pain processing were still beinig driven by peripheral 
nociceptive input, and thus disappeared with effective treatment of the source of pain. 
 
From the discussion above, poor inhibitory modulation of pain processing preoperatively 
might be expected to be linked to greater risk of persisting or chronic pain after surgery. 
Indeed, for thoracic surgery, a key study for the first time directly linked poor preoperative 
inhibitory pain modulation (CPM paradigm) and higher incidences of chronic pain 30 weeks 
postoperatively 95. For major abdominal surgery, my group has confirmed this result, linking 
the presence of chronic pain six months after surgery to poorer preoperative inhibitory pain 
modulation of the skin (CPM paradigm using electric skin pain thresholds). In addition, I was 
able to demonstrate that the persistence of heterotopically spreading hyperalgesia 
(mechanical muscle pain thresholds in the leg) up to three months postoperatively (Figure 
13, below) as a sign of rostral neuraxial spread and persistence of central sensitisation was 
also linked to poorer preoperative inhibitory pain modulation, this time of the muscle (CPM 
paradigm using mechanical muscle pain thresholds) (XIII). 
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Figure 13: Patients with chronic pain six months after major abdominal surgery (with CP) show persisting 
spreading heterotopic hyperalgesia (measured in leg muscle using pressure pain tolerance thresholds, pPTT) for 
the first three months postoperatively, while patients without chronic pain (no CP) do not. Degree of 
heterotopic hyperalgesia in the leg was inversely correlated with preoperative inhibitory modulation of leg 
pressure pain thresholds (CPM paradigm). Values are means and 95% confidence intervals. Reproduced with 
permission from reference XIII. 
 
In summary, we now possess evidence that generalized hyperalgesia and poor inhibitory 
modulation are present preoperatively in some patient groups at high risk for postoperative 
chronic pain development. These changes in pain processing resemble those present in 
chronic pain patients. Poor preoperative inhibitory modulation has been directly linked not 
only to increased incidences of chronic pain after surgery, but also to persistent spreading 
hyperalgesia indicative of supraspinal central sensitisation after surgery. These findings 
further emphasize the importance of preoperative QST screening via NASQ to achieve 
SATAPP.QST in the surgical context and thus improve long-term outcomes after surgery. 
 
4.3.2. Early Postoperative Period: First Week 
Our studies demonstrate that the first 24 hours after surgery are dominated by generalized 
skin hypoalgesia, probably reflecting descending inhibitory modulation, and greater with 
better intraoperative analgesia (Figure 14, below) (I, II, VI). Hypoalgesia decreases 
subsequently, becoming overt generalized hyperalgesia by postoperative day 5 in back 
surgery – but not abdominal surgery – patients (I, II, VI). The generalized hyperalgesia in back 
surgery patients at the end of the first week is reduced by pre-emptive opioids, but not by 
NSAIDs such as ketorolac (I, VI). Such early hyperalgesia is also increased in patients 
reporting pain preoperatively, as mentioned earlier 178. This hyperalgesia is likely a reflection 
of the now well-documented, frequent neuropathic elements in back pain 194-196 and their 
resulting undesirable effects on passive and active pain processing, typically relatively 
resistant to opioid therapy 53,140,197-199. 
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Figure 14: Patients after back surgery show a predominantly hypoalgesic response, greater in the presence of 
analgesic opioid (fentanyl) supplementation, for the first 24 hours postoperatively. Five days postoperatively, 
significant segmental and spreading hyperalgesia appears, predominantly in the placebo group. Vertical axis 
shows change in electric pain tolerance thresholds vs. preoperatively (in mA). The upper horizontal axis shows 
time postoperatively in hours; the lower horizontal axis shows site of threshold measurement (arm, peri-
incisionally, leg). Values are means and 95% confidence intervals. Modified from reference I. 
 
Surgical incision is surrounded by hyperalgesic skin in the early postoperative period (from 
day 1 of the first postoperative week) as a reflection of spinal central sensitisation 40. This 
area increases in size at least up to the third day postoperatively and is decreased by 
effective perioperative antinociception such as epidural analgesia, or by antihyperalgesic 
drugs such as ketamine or clonidine 40-42. Increased areas of such peri-incisional (or 
secondary) hyperalgesia have now been demonstrated to be associated with higher rates of 
chronic pain up to one year after abdominal surgery 40-42. 
 
Our group has demonstrated that the degree of early peri-incisional (secondary) 
hyperalgesia after surgery (i.e. thresholds) is also decreased by a variety of analgesic drugs as 
supplements to intraoperative anaesthesia (I, VI). In these studies we were additionally able 
to demonstrate the presence of spreading/generalised hyperalgesia. This finding is 
compatible with supraspinal central sensitisation already being present in the early 
postoperative period, and was also affected by intraoperative analgesic supplementation. 
 
Furthermore, we have also for the first time linked greater degrees of hyperalgesia in the 
early postoperative period to the presence of chronic pain six months after abdominal 
surgery (XIII). Of note is the fact that this link applies not only to secondary skin hyperalgesia, 
but equally to spreading or generalised skin hyperalgesia. Moreover, greater degrees of 
spreading or generalised hyperalgesia were also seen heterotopically, namely in mechanical 
muscle pain thresholds. This suggests that supraspinal spread of central sensitisation can 
occur early in a subgroup of patients susceptible to chronic pain after surgery. 
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Of note is the fact that in all of the studies cited, there is only a weak correlation between 
postoperative changes in pain processing, as detected by QST, and postoperative clinical 
measures of pain experience, such as pain VAS or analgesia consumption. Thus the detection 
of hyperalgesia in the clinical context requires the performance of formal QST and cannot 
reliably be inferred from clinical measures of the pain experience 40-42 (I, II, VI, XIII). 
 
In summary, there is accumulating data about hyperalgesia – both secondary and 
generalized – in the first week after surgery as a reflection of spinal and supraspinal central 
sensitisation. Extent and degree of hyperalgesia are favourably influenced by antinociceptive 
and antihyperalgesic interventions. In surgical patient groups vulnerable to poor long-term 
pain outcomes, spread of central sensitisation to supraspinal centres can occur early. My 
group has presented first evidence that links greater extent and degree of early 
postoperative hyperalgesia with more chronic pain later on. Thus QST monitoring of spread 
and persistence of hyperalgesia using NASQ in the early postoperative period is fundamental 
to achieving better pain outcomes after surgery in the context of perioperative SATAPP. 
 
4.3.3. Late Postoperative Period: Months to Year 
Few studies documenting longer-term altered pain processing after surgery have been 
published to date. Some studies are available linking hyperalgesia at a given time point after 
surgery with the presence of chronic pain, including mastectomy, hip replacement, 
maxillofacial or inguinal hernia surgery 118,200,201. Sensory findings compatible with nerve 
damage are often also demonstrated in these studies. My group has recently documented 
the time course of pain and altered pain processing for six months after abdominal surgery 
(XII) (Figure 13, below). Postoperative pain VAS was negatively correlated with preoperative 
pain modulation (CPM/DNIC) of the skin, particularly at six months. Patients with chronic 
pain six months postoperatively showed consistently more peri-incisional and 
spreading/generalized skin hyperalgesia over the six-month postoperative period. The 
chronic pain group also displayed more distant deep tissue hyperalgesia. This hyperalgesia 
was negatively correlated with preoperative inhibitory deep tissue pain modulation. Of note 
was that differences in postoperative pain VAS between groups reporting pain or no pain six 
months after surgery only became apparent and significant from three months 
postoperatively. 
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Figure 15: Patients with chronic pain six months after major abdominal surgery (with CP) show persisting 
secondary and spreading skin hyperalgesia (measured in abdominal and leg skin using electric pain tolerance 
thresholds, ePTT) for the first six months postoperatively, while patients without chronic pain (no CP) do not. 
Values are means and 95% confidence intervals. Reproduced with permission from reference XIII. 
 
The data presently available regarding pain processing in the late postoperative period 
suggests that patients suffering persistent, chronic pain after surgery exhibit spinal and 
supraspinal central sensitisation, manifest as peri-incisional and generalized hyperalgesia. 
This finding is similar to the changes in sensory processing found in patients suffering chronic 
pain of non-surgical origin.  
 
In summary, we now possess first evidence that chronic pain development after surgery is 
associated with heterotopic (affecting both skin and deep tissue) persistence and spread of 
hyperalgesia. Both increased pain experience and hyperalgesia spread appear to be favoured 
by poor inhibitory pain modulation preoperatively. There is again a lack of correlation 
between objective measures of altered pain processing and subjective reported pain 
experience. All of these factors indicate the importance of ongoing QST monitoring for 
hyperalgesia and pro-nociceptive modulation using NASQ to achieve effective SATAPP.QST 
and improve pain outcomes in the late postoperative period. 
 
4.4. Summary: Clinical Perioperative Application of SATAPP.QST 
In summary, my perioperative pain research distinguishes itself by being the first to 
investigate the dynamic spreading and heterotopic nature of the sensory phenomena 
involved over a long postoperative follow-up period, regarding not only central sensitisation, 
but also its inhibitory modulation. My research using NASQ has provided strong initial 
evidence to support the key role of persistence and spread of hyperalgesia during the 
development of chronic pain after surgery, and for the increased risk caused in this context 
by poor preoperative inhibitory modulation of pain processing as measured by CPM/DNIC 
paradigm. Furthermore, my research has confirmed the negative role of nerve damage and 
preoperative central sensitisation (expressed as pain and hyperalgesia) in this context. 
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Some important conclusions regarding the relevance of NASQ for achieving clinical 
implementation of SATAPP.QST can be drawn as a result: 
Firstly, pre-operative determination of effectiveness of inhibitory pain modulation via 
CPM/DNIC paradigm may be a predictive biomarker for risk of chronic pain development. 
Secondly, monitoring of persistence and spread of hyperalgesia after surgery may be a useful 
biomarker of ongoing vulnerability to chronic pain development. The risk for hyperalgesia 
appears to increase with pre/intratraoperative nerve damage and central sensitisation. 
Thirdly, it appears logical to posit that risk of developing chronic pain after surgery is 
decreased by therapeutic measures to diminish persistence and spread of hyperalgesia. This 
may be achieved by reducing nociceptive input and/or by targeting hyperalgesia, either 
directly by antihyperalgesic treatments or indirectly by improving inhibitory controls. 
Finally, implementation of these conclusions in everyday clinical practice isimpossible 
without objectively diagnosing altered pain sensitivity (hyperalgesia) and pain modulation 
(CPM paradigm) – and this is impossible without implementing QST diagnostics into clinical 
practice. e.g. via NASQ. My research demonstrates importance and value of perioperative 
QST monitoring in clinical pain practice, and shows that it practicable and feasible to do so. 
 
Based on these conclusions, I would like to put forward the following recommendations for a 
systematic approach to altered pain processing (SATAPP.QST) for managing perioperative 
pain aiming to improve acute and chronic pain outcomes (summarised in figure 16, below): 
 
Figure 16: SATAPP.QST for perioperative pain management. CS=central sensitisation, DM=descending 
modulation, TCA=tricyclic antidepressants, NRI=noradrenaline reuptake inhibitors. 
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4.4.1. Clinical Implementation: Preoperative Period 
Preoperatively, patients with a history suggestive of increased risk of poor pain outcomes 
(e.g. pre-existing chronic pain disorder; pre-existing chronic analgesic use, particularly 
opioids; extensive planned surgery; planned surgery with high risk of nerve damage or 
visceral pain; pain problems after previous surgery) should undergo screening quantitative 
sensory testing. This should include the flowing elements implemented in NASQ: 
 testing for pain sensitivity using electric pain thresholds (skin) and pressure pain 
thresholds (deep tissues) close to and distant from the planned surgical incision 
 testing for inhibitory pain modulation using the conditioned pain modulation 
paradigm involving electric skin and muscle pressure painful test stimulation and the 
cold pressor task as conditioning stimulation 
If generalised heterotopic hyperalgesia suggestive of supraspinal central sensitisation is 
detected: 
 considerer treating this preoperatively, e.g. using gabapentinoids or ketamine 
infusion 
If poor inhibitory modulation is detected: 
 particular attention to intraoperative antinociception and antihyperalgesia is 
recommended, e.g. locoregional anaesthesia, ketamine infusion or nitrous oxide 
supplementation 202-205 
 treatments possibly strengthening inhibitory controls should be considered, such as 
tricyclic antidepressants or other drugs affecting the monoaminergic systems (e.g. 
duloxitine 206) 
The effectiveness of therapeutic interventions should be monitored by subsequent serial 
NASQ measurements. 
 
4.4.2. Clinical Implementation: Intraoperative Period 
Intraoperatively, patients with factors suggestive of increased risk of poor pain outcomes 
need special attention to reduce intraoperative sensitisation of their central nervous system, 
including the following measures: 
 
 anaesthetic techniques targeting effective antinociception, e.g. the use of loco-
regional techniques continued into the postoperative period 
 use of medication limiting development of hyperalgesia, e.g. nitrous oxide or 
ketamine infusion extended into the postoperative period 
 application of surgical techniques avoiding/minimising nerve damage and limiting 
central sensitisation (local anaesthetic infiltration, reduced extensiveness of tissue 
damage via minimally invasive surgery) 
 
4.4.3. Clinical Implementation: Early Postoperative Period 
In the first postoperative week, patients need to be monitored using serial pain sensitivity 
measurements for development and persistence of spreading hyperalgesia, both 
nociception- and opioid-induced. This applies particularly to patients with factors suggestive 
of increased risk of poor pain outcomes. If hyperalgesia develops or persists, particularly of 
deep tissues such as muscle, the following should be considered: 
 institution/continuation of antihyperalgesic measures, e.g. ketamine infusion or 
gabapentinoids 
 starting treatments possibly strengthening inhibitory controls, e.g. tricyclic 
antidepressants or other drugs affecting the monoaminergic systems 206 
DSc (Aalborg) OWS 
Page 42 of 76 
 institution/continuation of effective antinociceptive measures, e.g. catheter local 
anaesthetic techniques 
The effectiveness of therapeutic interventions should be monitored by serial NASQ 
measurements. 
 
4.4.4. Clinical Implementation: Late Postoperative Period 
During the subsequent postoperative period (months to year), patients at risk should: 
 continue to be monitored using serial pain sensitivity measurements for persistence 
and spread of hyperalgesia, particularly of deep tissues such as muscle 
If hyperalgesia persists or spreads, consider: 
 institution/continuation of antihyperalgesic measures, e.g. gabapentinoids 
 dealing with ongoing nociceptive inputs, e.g. via long-term nerve blocks 
 also monitoring inhibitory function, e.g. via CPM paradigm, and starting treatments 
possibly strengthening inhibitory controls, e.g. tricyclic antidepressants or other 
drugs affecting the monoaminergic systems 206 
The effectiveness of therapeutic interventions should be monitored by serial NASQ 
measurements. 
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5. SATAPP.QST for Chronic Pain Practice 
5.1. The Problem of Chronic Pain 
5.1.1. Major Societal Impact 
Chronic pain continues to be a costly and prevalent medical and societal problem with an 
estimated point prevalence of ca. 15-19% in Western societies 207,208. About 35% of these 
patients report that the chronic pain significantly interferes with their daily activities of living 
209. The picture is even worse when considering treatment of chronic pain, where no 
treatment at present used eliminates pain for the majority of patients 210. Thus, for example, 
use of anticonvulsants and antidepressants for chronic pain will achieve a 50% reduction in 
pain ratings in only one patient out of three 211. The results of interventional treatments are 
even worse, e.g. between two thirds and three quarters of patients undergoing back surgery 
for pain will continue to experience pain for many years after surgery 212-214. 
 
5.1.2. Symptom-based Approaches 
This major problem facing pain medicine must be viewed in the context of the continuing 
symptom-based nature of our present diagnostic and therapeutic approaches to chronic 
pain. The history of medical progress suggests that most advances towards effective 
treatment are the result of better understanding and diagnostics of mechanisms underlying 
a given disease and its development 76,215. Such understanding and diagnostics of pain 
diseases is largely lacking for the clinical chronic pain patients at present, and explains the 
poor therapeutic performance of pain medicine 76,198,215,216. Thus the first and foremost 
challenge for clinical pain research is to understand the alterations in pain processing 
operating in patients with chronic pain, and to devise methods of diagnosing these in the 
clinical context. 
 
5.1.3. Achieving SATAPP.QST 
The basis for achieving a systematic approach to altered pain processing for chronic pain is 
an understanding of underlying changes in central pain processing. As previously mentioned, 
understanding and diagnosing altered central pain processing and its nature is key to 
answering the four questions regarding nociceptive processing in pain conditions, namely  
1) nociceptive source, 2) nociceptive transmission, 3) altered central pain processing and  
4) possible autonomy of altered central pain processing. My research programme on chronic 
pain has focussed on questions three and four. Based on NASQ, I have concentrated on the 
diagnosis and quantification of spreading and generalised hyperalgesia as a manifestation of 
sensitised supraspinal pain processing, and its dependence on peripheral nociceptive drive 
(V, VII, VIII, IX, X, XIV, XV). I chose this topic as a continuation of my research programme on 
the relationship between the development of hyperalgesia and persistent pain after surgery. 
 
As already discussed above, rostral neuraxial spread of central sensitisation manifest as 
spreading and generalised hyperalgesia seems to be a candidate process for the 
development of chronic pain 25-27. Spreading or generalised hyperalgesia is now recognised 
as a feature of many chronic pain syndromes, being associated with extensive central 
excitation including supraspinal central sensitisation and cortical reorganisation as well as 
pro-nociceptive descending pain modulation states 25,26,33,35,43,49,60,61,66,78,95,159,163. 
 
Therapeutically, diagnosing generalised hyperalgesia as a marker for central sensitisation is 
important in the context of chronic pain because the underlying presence of central 
sensitisation means that treatments addressing peripheral nociceptive input alone are 
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unlikely to be successful, likely requiring own specific, targeted therapeutic measures 187,197. 
Taking these aspects together, there is a clear need to be able to validly and reliably 
diagnose spreading or generalised hyperalgesia in chronic pain patients – not only as a 
descriptor of the central sensitisation exhibited, but also as a marker of disease progression. 
 
5.2. Summary of Current Knowledge: Neuroplasticity and Chronic Pain 
5.2.1. Spreading Central Sensitisation of Nociceptive Processing 
Evidence for the presence of generalized deep tissue hyperalgesia as a sign of supraspinal 
central sensitisation is now available in a large number of chronic pain conditions. In most 
cases this increased sensitivity to pain is demonstrated by psychophysical testing or QST, i.e. 
via pain magnitude ratings to standardized pain stimuli or via the determination of pain 
thresholds 51,52,55,56,67,68,79,91,217. Using such methods, supraspinal central sensitization with 
chronic pain has now been demonstrated, e.g., in low back pain 45,57,176,177,194, fibromyalgia 
44,46,48,80,105,109,160,218-222, rheumatoid arthritis 218,223,224, osteoarthritis 32,82,218,225, chronic 
widespread pain 48,219, irritable bowel syndrome 50,226,227, pancreatitis 228,229, gallstones 230 
and headache 181. 
 
5.2.2. Pro-nociceptive Shifts in Pain Modulation 
Further support for supraspinal alterations of pain processing is provided via evidence for 
loss of DNIC or descending facilitation using conditioned pain modulation (CPM) paradigms, 
e.g. involving the cold pressor task 112,231-233. Evidence for such pro-nociceptive supraspinal 
modulation of pain processing accompanying chronic pain is available for a number of 
conditions including fibromyalgia 46,48,80,96,160,222, muscle 94, headache 181, osteoarthritis 32,225, 
irritable bowel syndrome 50,227, and rheumatoid arthritis 223. 
 
5.2.3. Sensitisation of Non-nociceptive Cortical Processing 
In addition to mentioned signs of sensitized supraspinal pain processing, there is now 
increasing evidence for the presence of sensitisation of non-nociceptive supraspinal 
processing in the context of chronic pain disorders. Thus chronic low back pain has been 
linked to sensitized taste 234 and more extensive CRPS to sensitized hearing (hyperacusis) 235. 
First evidence is now available showing alterations in affective and cognitive processing in 
chronic pain patients using a variety of cognitive function tests 29,78,149,221,236-238. The 
application of modern neuroimaging (e.g. fMRI) and neuroelectrophysiological (e.g. source 
localization with multichannel EEG) techniques has made it possible to directly demonstrate 
cortical reorganization, altered connectivity and modulation associated with central 
sensitisation in association with chronic pain conditions such as CRPS 49,239,240, irritable bowel 
syndrome 227, pancreatitis 241-246, low back pain 78,163,236,247-249, fibromyalgia 44,48,80,160,220-
222,250-254, and after amputation 255-259. Indeed, it is not only specific non-nociceptive 
supraspinal processing which has been shown to be altered in chronic pain, there is now 
early data showing that even the global resting state of the brain is altered in chronic pain 
patients 149,248. Furthermore, recent neuroimaging studies have demonstrated atrophy and 
brain substance loss in supratentorial structures to be present in a variety of chronic pain 
conditions 163,242,243,246,247,249. 
 
There is thus now ample evidence that the chronic pain state is associated with supraspinal 
and supratentorial changes in brain processing, affecting not only nociceptive but also non-
nociceptive processing. These changes are manifest as generalized hyperalgesia (particularly 
of deep tissues), alterations in non-nociceptive sensory processing, and the changes in 
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cognitive, affective, mental or psychological function so characteristic of – and so well 
described in – chronic pain patients. 
 
5.3. Synopsis of Own Contributions 
5.3.1. Defining the Patients 
In the course of my research, we chose four groups of patients with chronic pain of various 
aetiologies and durations, and affecting different tissues or systems. In the first instance, this 
choice was made in order to be able to study a wide variety of chronic pain patients. Equally 
important, this choice of patients also enabled the study of interesting and relevant other 
aspects of chronic pain, particularly 1) effects of disease duration and progression in relation 
to altered pain processing, and 2) relationships between peripheral nociceptive input and 
central alterations in pain processing. The patients groups I chose are briefly described in the 
following. 
 
5.3.1.1. Neuroinflammatory Pain: Complex Regional Pain Syndrome (CRPS) Type I (VII) 
We recruited patients diagnosed some eight years previously as having CRPS I according to 
the Veldman criteria 152, sub-diagnosis warm or cold, of a single upper extremity (V). All 
these patients had undergone a one-year standardised multidisciplinary therapy after 
diagnosis. Based on the answers to questioning, a disease progression score (DPS) was 
assigned to each patient: DPS 0 = no significant pain, no extension of CRPS to the other 
extremity; DPS 1 = significant pain, no extension; DPS 2 = significant pain and extension to 
another extremity. One of the major goals of this study was to define the relationship 
between progression of neuroinflammation and changes in central pain processing, e.g. the 
development of central sensitisation. 
 
5.3.1.2. Combined Somatic and Neuropathic Pain: Low Back Pain (V) 
The low back pain patients suffered from low back pain radiating into the leg with a duration 
of between one month and one year, and were now waiting for surgery of their prolapsed 
intervertebral disc. Their pain had been greater than visual analogue scale (VAS) 5 for more 
than three quarters of the time for at least one month, accompanied by typical symptoms 
and signs of sciatic pain. In addition they all had a significant intervertebral disc prolapse 
confirmed by neuroimaging. The indication for surgery was thus mainly based on pain, not 
on neurological impairment. All patients had furthermore undergone a (failed) trial of 
conservative treatment. Three days before surgery all were started on a standard anti-
inflammatory regime of diclofenac 3 X 100 mg po. We studied all patients on the day before 
surgery under diclofenac treatment, some were pain-free under this regime, others not. The 
main emphasis of my research here was to study the impact of adding neuropathic pain to 
inflammatory somatic pain on the development of central sensitisation expressed as 
spreading hyperalgesia. 
 
5.3.1.3. Viscero-Somatic Pain: Chronic Pancreatitis (VIII, IX, XIV, XV) 
Our group has generated a unique body of knowledge regarding central alterations in pain 
processing in chronic pancreatitis patients. For two studies (VIII, XIV), we recruited patients 
having suffered from severe pain due to chronic pancreatitis, mean duration 4-5 years, who 
were at present stable on opioid analgesic medication. None had experienced complications 
of chronic pancreatitis, undergone abdominal surgery, or suffered from other chronic pain 
syndromes. For comparison, we recruited a group of pain-free age- and gender-matched 
patients due to undergo minor, benign urological or gynaecological surgery as controls. The 
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other two studies (IX, XV) included chronic pancreatitis patients scheduled for pain-relieving 
surgery, i.e. bilateral thoracoscopic splanchnicectomy (BTS). The indication for BTS was 
severe continuous or intermittent pancreatic pain necessitating continuous opioid 
medication for the last six months in combination with several unsuccessful attempts to 
reduce (or discontinue) opioid medication. At the time of preoperative measurement, these 
patients were stable on their opioid medication, none had complications of pancreatitis or 
other chronic pain syndromes. Patients’ pain and pain processing were assessed before and 
ca. six weeks after BTS. Again we recruited a set of age- and gender-matched controls for 
comparison as necessary. This set of studies investigates 1) the effect of ongoing visceral 
nociceptive input on central sensitisation of somatic pain processing, 2) the effects on 
central somatic pain processing of deafferenting ongoing visceral nociceptive input, and 3) 
the effects of acute NMDA receptor blockade on the central sensitisation resulting from 
ongoing visceral nociceptive input. 
 
5.3.1.4. Viscero-Visceral Pain: Dysmenorrhoea 
This study (X) recruited pre-menopausal women with significant dysmenorrhoea from a 
gynaecological outpatient’s clinic. The patients suffered recurrent abdominal pain an 
average of eight years with a VAS intensity of over 60 mm related to the menstrual cycle, but 
were free of any other gastrointestinal symptoms or disorder, and did not suffer from any 
other pain disorder. For comparison, a matched health control group was recruited. All 
patients were measured mid-cycle to minimize effects of the menstrual cycle. The main aim 
of the study was to research whether ongoing visceral nociceptive input (e.g. due to 
dysmenorrhoea) results in sensitisation of convergent central visceral pain processing in 
other visceral structures (e.g. colon and rectum). 
 
5.3.2. Characteristics of altered pain processing in chronic pain patients 
All the chronic pain conditions we studied were accompanied by hyperalgesia, irrespective 
of duration and type of chronic pain studied, i.e. short and long-lasting; somatic, visceral and 
neuropathic. These results add to the growing body of clinical and experimental evidence 
linking chronic pain and hyperalgesia 32-34,45,46,50,105,142,150,176,260,261. Our most consistent 
finding using NASQ was generalised hyperalgesia to pressure algometry; results using 
cutaneous electrical stimulation were more variable. 
 
Pressure algometry results in stimulation of mechanoreceptors, mostly of deep tissues such 
as muscle, with only minor contributions from skin inputs 89,105,106. It can therefore be 
considered to reflect changes in deep tissue pain processing, such as the mechanical 
hyperalgesia associated with central sensitisation 89,105,106. Transcutaneous electrical 
stimulation, which reflects mainly pain processing originating from the skin, bypasses skin 
nociceptors, stimulating the nociceptive nerve afferents directly 108,109. Electric thresholds 
thus effectively reflect more central changes in cutaneous pain processing, being sensitive to 
both excitatory (e.g. central sensitisation) and inhibitory (e.g. DNIC) changes 46,107-109. 
 
My studies link chronic pain syndromes to spreading or generalised heterotopic hyperalgesia 
which is mechanical and affects deep somatic tissues, in our case muscle, in keeping with the 
literature regarding chronic pain 32,45,50,105,176,260. The presence of spreading or generalised 
hyperalgesia in these patients is compatible with a variety of possible underlying 
pathophysiological processes: Firstly, it may indicate that central sensitisation is spreading 
rostrally up the neuraxis to involve supraspinal structures 30,31,142,150. Secondly, this pattern of 
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hyperalgesia might be a reflection of the involvement of perispinal macroglia, which can be 
sensitised by humoral as well as neuronal mechanisms 262,263. A third possible cause for 
generalised hyperalgesia in chronic pain patients is opioid-induced hyperalgesia, which 
shares many of the same mechanisms as nociception-induced hyperalgesia. This typically 
accompanies longer-term, escalating, use of potent opioids – which is typical for many 
chronic pain conditions, and is now well-described in the literature in the animal 
experimental as well as human clinical context 27,111,264-269. 
 
The reality of the first-mentioned mechanism in chronic pain patients is now well-
demonstrated by human clinical studies using advanced neurodiagnostic and neuroimaging 
techniques 49,78,159,163,236,239. The second mechanism is well-documented experimentally 
262,263,270-273 but awaits similar clinical confirmation. The third mechanism, opioid-induced 
hyperalgesia, is also quite well studied experimentally. It has also been demonstrated in 
human volunteers and humans 111,264,274-276. Once these processes have persisted for longer 
periods of time, they may become progressively more difficult to reverse and increasingly 
involve architectural as opposed to purely functional changes, with the accompanying 
hyperalgesia thus becoming gradually more autonomous, i.e. less dependent on the original 
peripheral nociceptive inputs 25,161,162,270. The postulated course of events is summarised in 
Figure 17, below. 
 
 
Figure 17: This schematic illustrates the concept of neuraxial proliferation of central sensitisation as the basis 
for development of generalised hyperalgesia in chronic pain. Each stage of rostral spread of central 
sensitisation is subject to descending modulatory control from superior segments; if descending inhibitory 
control is inadequate further rostral spread of sensitisation occurs. Note that modulatioin can be either 
inhibitory or facilitatory. A central question in chronic pain is whether the central sensitisation present is still 
dependent for its persistence on ongoing caudal nociceptive inputs. 
 
The effects of chronic pain on skin electric pain processing were more variable than on 
pressure algometry. Acute pain typically results in descending inhibitory modulation to the 
skin – if this inhibitory system is intact, which may not always the case in chronic pain 
patients 35,46,230,244. The fact that in our study of low back pain patients (V), acute sciatica was 
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related to higher pain thresholds suggests that in these relatively short-duration chronic pain 
patients, descending inhibitory modulation was still intact, although we did not formally test 
this, e.g. using the CPM paradigm. The presence of deep tissue hyperalgesia does not appear 
to necessarily translate into skin hyperalgesia. For example, for the chronic pancreatitis pain 
of visceral origin, skin hyperalgesia seems to be the exception rather than the rule, as also 
described by others for visceral pain 230,260. On the other hand, in both low back pain 
patients (which have generalised muscle hyperalgesia 45) and “cold” CRPS I patients (which 
also exhibit muscle hyperalgesia 277), some form of generalised cutaneous hyperalgesia to 
electrical stimulation was present in our studies (V, VII). 
 
My studies provide evidence that central sensitisation spreads in the neuraxis with ongoing 
nociceptive input, a process expressed as the phenomenon of spreading hyperalgesia. This 
spread can firstly be heterotopic within somatic tissues, e.g. somato-somatic spread from 
muscle to skin, as seen in low back pain, CRPS or chronic pain after surgery. As seen in the 
CRPS patients, this spread seems to be related to disease progression. Secondly, viscero-
visceral spread of central sensitisation is equally possible, as illustrated by the 
dysmenorrhoea study with spread of hyperalgesia from gynaecological to intestinal viscera. 
Finally, this spread may even be viscero-somatic, as seen in the chronic pancreatitis patients 
with their hyperalgesia to muscle stimulation. 
 
We would therefore suggest that the persistence and spread of hyperalgesia should be 
considered diagnostically characteristic of chronic pain. Heterotopic spread of hyperalgesia, 
particularly to deep tissues, appears to be associated with more severe pain disorder in this 
context. Thus the diagnosis and quantification of spreading or generalised heterotopic 
hyperalgesia appears to be of key importance in chronic pain, because its presence signals 
the existence of prognostically serious alterations in pain processing. Also seen in the 
context of chronic pain persistence after surgery 178 (XIII), these alterations risk becoming 
progressively more difficult to influence by measures blocking peripheral nociceptive inputs 
– and thus increasingly difficult to influence or reverse. Diagnosing such hyperalgesia 
provides the basis for specific treatment targeting central sensitisation, pro-nociceptive 
shifts in central pain modulation and allied changes to the central nervous system in chronic 
pain patients, mechanisms frequently only inadequately addressed by current conventional 
treatment regimes. 
 
5.3.3. Disease progression and diagnostic subgroups 
Not only does generalised hyperalgesia accompany chronic pain syndromes, it also seems 
that the degree of spreading or generalised hyperalgesia may be linked to the progression of 
chronic pain syndromes. I specifically tested this hypothesis in our CRPS study (VII), 
confirming that, eighth years after original diagnosis, the degree of muscle pressure 
hyperalgesia was increased with increasing disease progression (as defined by extension to 
other extremities), as also suggested by other authors for CRPS and hyperalgesia 49,239,278,279. 
I further found that hyperalgesia measured by pressure algometry was consistently greatest 
in the originally affected extremity. 
 
Although both “warm” and “cold” CRPS I exhibited muscle hyperalgesia, these findings were 
more pronounced in diagnostic subgroup “cold” CRPS patients. These same “cold” CRPS 
patients also had worse clinical pain outcomes eight years after original diagnosis. Only in 
this group did degree of pressure hyperalgesia significantly correlate with clinical pain 
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outcome measures. Interestingly, hyperalgesia to suprathreshold electrical skin stimulation 
was seen only in the “cold” diagnostic subgroup – and occurred in the absence of shifts in 
electric skin pain thresholds. Furthermore, this hyperalgesia was also linked to disease 
progression (Figure 18, below). Suprathreshold hyperalgesia is considered to be more 
reflective of sensitisation of supraspinal pain processing than hyperalgesia at threshold 29. 
These findings support the hypothesis that central sensitisation is more severe and extensive 
in patients diagnosed with “cold” CRPS. They further suggest that in “cold” CRPS I patients, 
extensive rostral neuraxial progression of central sensitisation of pain processing, linked to 
disease progression as well as poorer clinical outcome, has taken place. This appears not to 
be the case for “warm” CRPS patients, even eight years after diagnosis, where central 
sensitisation does not explain disease progression or clinical outcome. Thus rostral neuraxial 
progression of central sensitisation would appear to be a major underlying mechanism in 
“cold” CRPS I patients, while other mechanisms would appear to be operating in “warm” 
CRPS I patients. 
 
 
Figure 18: Pressure pain thresholds (in kPa; means and 95% confidence intervals) in CRPS I patients were 
significantly lower on the affected (vs. unaffected) side. They were also lower with increasing disease 
progression (DPPS). DIAG, original diagnosis (i.e. warm or cold CRPS 1); DPPS, disease pain progression score (0, 
no significant pain; 1, significant pain only in affected extremity; 2, significant pain in affected extremity plus 
extension to other extremity). Reproduced from study VII with permission. 
 
Our results regarding the presence of central sensitisation in CRPS I patients are well-
supported by an extensive body of literature using both QST and neurodiagnostic techniques 
to demonstrate central sensitisation and cortical reorganisation 49,239,240,277,280. However, 
these studies neither differentiate between diagnostic subtypes, nor provide a link with 
disease progression, nor demonstrate the conjunction of deep tissue threshold hyperalgesia 
with cutaneous suprathreshold hyperalgesia seen in our study for “cold” CRPS I. 
 
We conclude that 1) more severe and extensive hyperalgesia, particularly of muscle, is 
related to greater disease progression in CRPS I, and 2) “cold” (vs. “warm”) CRPS I patients 
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have signs of more prominent and extensive central sensitisation associated with a worse 
clinical prognosis. Interestingly, this intuitively attractive concept of a relationship between 
disease progression, disease subtypes and extent/severity of central sensitisation has not yet 
been applied to other clinical pain syndromes to date, and awaits further formal studies. 
 
QST diagnostics regarding presence, degree, extent and modality patterns of hyperalgesia 
would appear to have realistic and useful potential to clinically quantify disease progression 
in the context of chronic pain syndromes. Furthermore, QST makes possible first attempts at 
mechanism-based diagnostic categorisation of chronic pain syndromes as a basis for more 
rational and effective treatment approaches, e.g. targeted specifically at the management of 
central sensitisation as opposed to conventional therapy directed at nociceptive inputs. 
 
5.3.4. Gender effects 
The healthy control subjects in our chronic pancreatitis studies showed characteristic 
gender-related differences in pain processing. As reported in the literature, men had 
significantly higher pressure pain tolerance thresholds than women, without significant 
differences in pain sensitivity to electric stimulation 107,108,281. The same pattern of lower 
pressure pain thresholds in women was also seen the pancreatitis patients. Interestingly, on 
reanalysis of our CRPS study (unpublished, reanalysis of VII), increased pain sensitivity in 
females was found not only for pressure pain thresholds, but also for electrically evoked pain 
in patients with the more serious, “cold” form of CRPS (Figure 19, below). 
 
 
Figure 19: For “cold” CRPS 1 patients, electrically evoked pain (VAS in mm; means and 95% confidence 
intervals; at 100%, 125% and 150% of pain threshold) was significantly higher in females. DIAGN, original CRPS 
diagnosis (i.e. warm or cold). Reanalysis of results from study VII. 
 
The results showing quite different responses regarding central pain processing of men vs. 
women to the chronic visceral nociceptive input of chronic pancreatitis are entirely novel, 
and were restricted to the study involving pancreatitis patients not having undergone 
previous abdominal surgery. Thus men appear to respond to chronic visceral nociceptive 
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input by developing generalised somatic deep tissue hyperalgesia. Women do not develop 
such generalised hyperalgesia (at least not to the same degree), instead they exhibit 
localised hypoalgesia to electric skin stimulation in the referred pancreatic dermatome. This 
is consistent with a segmental inhibitory response, which appears effective in limiting the 
development of generalised deep tissue hyperalgesia. 
 
There are thus fundamental gender differences in the consequences of ongoing pancreatic 
nociceptive input regarding pain processing. While there are some reports detailing 
differences in pain processing between men and women, these mainly concern differences 
in pain sensitivity, often connected with the menstrual cycle 67,68,107,108,276,281-285. Gender 
differences in the response to ongoing nociceptive input and its modulation are only 
sparsely described in the literature to date, particularly in the human, clinical context. 
Human gender differences have been reported concerning stress-induced analgesia as well 
as supraspinal descending noxious inhibitory control (DNIC) mechanisms 96,284,286, but we 
have found no mention of gender differences in segmental inhibitory mechanisms. These 
differences might be related to specific adaptations of female pain processing to the pain 
associated with childbirth. However, there is no literature available in this area at present, 
and further research is clearly indicated in this field. 
 
The importance of diagnosing gender differences regarding alterations in pain processing in 
chronic pain diseases using QST is evident, because such diagnosis provides the necessary 
basis for subsequent treatment approaches targeting altered pain processing. 
 
5.3.6. Effects of antihyperalgesic treatment 
If central sensitisation manifest as heterotopic spreading hyperalgesia is a key mechanism in 
chronic pain, then it would be important to define and validate effective treatments for this 
condition. It is known that the NMDA receptor plays an important role in the development 
of central sensitisation, and NMDA receptor blockade has been experimentally 
demonstrated to inhibit central sensitisation 188,197,199,287-292. Ketamine is a clinically available 
NMDA receptor blocker, and has been shown to improve pain outcomes after surgery 
37,40,187,190-192,293,294 – and to reduce opioid-induced hyperalgesia when used perioperatively 
186,295. My study is the first to demonstrate the targeted use of a short-term infusion of 
ketamine to achieve acute inhibition of heterotopic spreading hyperalgesia in chronic 
pancreatitis patients with severe pain (figure 20, below) (XIV). However, the infusion 
duration was too short to achieve significant decreases in clinical pain experience, 
illustrating the urgent need for further research in this field involving longer-term treatment 
approaches. The promise of pursuing such approaches targeting altered pain processing in 
severe chronic pain syndromes such as chronic pancreatitis is supported by a recent 
companion publication from our group, demonstrating the analgesic efficacy of another 
central antihyperalgesic agent, pregabalin, in relieving the pain of chronic pancreatitis 296. 
Taken together, these results further underline the usefulness of QST in the management of 
chronic pain, not only in achieving a choice of pharmacological agent based on effects on 
pain processing, but also by providing a means of monitoring treatment effect and response. 
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Figure 20: A. The change in sum of pressure pain thresholds (SOPPT, in kPa) immediately after the end of 
infusion versus before infusion of the trial medication compared for the placebo and S-ketamine groups. B. The 
change in SOPPT versus before infusion 1 hr after the end of infusion of the trial medication compared for the 
placebo and S-ketamine groups. The difference between groups immediately after the end of the infusion is 
significant – but not 1 hour later. Reproduced with permission from reference XIV. 
 
5.3.7. Effects of nociceptive deafferentation 
One of the key questions regarding the spreading hyperalgesia accompanying chronic pain 
syndromes is how dependent is the supraspinal central sensitisation which it reflects on 
ongoing nociceptive input for its maintenance 161,162. The clinical use of bilateral 
thoracoscopic splanchnicectomy (BTS), an operation effectively leading to sensory 
denervation of the pancreas as a means of treating otherwise intractable pain accompanying 
chronic pancreatitis 297,298, provides an interesting opportunity to study the dependence of 
spreading hyperalgesia on ongoing nociceptive inputs. We studied this phenomenon in two 
groups of chronic pancreatitis patients undergoing BTS for chronic intractable pain. 
 
In the first study BTS resulted in cessation of opioid therapy in about half the patients, who 
also showed a trend towards lower pain scores. There was, on average, a generalised 
increase in both deep tissue mechanical and cutaneous electric pain thresholds 6 weeks 
after BTS, suggesting that the supraspinal central sensitisation present in these patients is at 
least partially dependent on pancreatic nociceptive inputs. Male chronic pancreatitis 
patients underwent reversal of their generalised pressure hyperalgesia with BTS, while 
women showed increased segmental inhibition, particularly in those reporting clinical 
treatment success. At the time, we explained our heterogeneous findings in part by our 
choice of a relatively insensitive clinical pain endpoint. Further possible explanations 
included the presence in some patients of autonomous central sensitisation (i.e. 
independent of nociceptive input 161,162), incomplete nociceptive deafferentation (e.g. due to 
surgical failure or because of ongoing pancreatic nociceptive input to the central nervous 
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system via humoral mediators such as cytokines or interleukins 262,263,272,299), or the act of 
deafferentation itself causing additional central sensitisation 25,31,257-259,290,300. 
 
We studied BTS effects on central pain processing and its relation to clinical pain experience 
in more detail in the second study. Overall I demonstrated a negative correlation between 
change in pain VAS and change in pressure pain thresholds after BTS. A key finding was that 
patients where BTS resulted in a decrease in spreading hyperalgesia also showed a 
significant reduction in pain VAS. Patients where BTS caused no decrease (or even increase) 
in hyperalgesia showed no significant pain reduction (figure 21, below). Interestingly, no 
such relation could be demonstrated for pancreatic segment hyperalgesia. These results 
suggest that in one group of pancreatitis patients treated by BTS (ca. 60%), central 
sensitisation expressed as spreading hyperalgesia is still dependent on peripheral 
nociceptive drive, and thus deafferentation by BTS results in pain reduction. In the other 
group (ca. 40%), central sensitisation has become independent of peripheral drive, thus 
deafferentation via BTS neither reduces hyperalgesia nor decreases pain. 
 
 
Figure 21: Box plots of change in pain numeric rating scores (NRS) vs. direction of change in pressure pain 
thresholds (PPT) after BTS. PPT was measured in the clavicle and pancreas dermatomes. A. The change in pain 
NRS after BTS was significantly greater (marked with an asterisk) in patients hypoalgesic (vs. preop) in the 
clavicle site after BTS. B. This was not the case for the pancreatic site. The hypoalgesic group experienced an 
increase in PPT after BTS (i.e. a reduction in preoperative hyperalgesia), the hyperalgesic group was the group 
not experiencing such an increase. Reproduced with permission from reference XV. 
 
We have found only one report in the literature addressing the question of reversibility of 
central sensitisation, and its dependence on ongoing nociceptive input 32. This study 
demonstrated generalised deep tissue hyperalgesia to pressure algometry in patients with 
painful chronic osteoarthritis of the hip joint. The hyperalgesia (and the accompanying 
deficit of descending inhibitory modulation) was no longer present 6 months after 
endoprosthetic hip surgery rendering the patient pain-free. For the chronic osteoarthritis 
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patients studied, this strongly suggests that central sensitisation and accompanying 
generalised hyperalgesia are reversible and dependent on ongoing nociceptive input for 
their maintenance. 
 
The question of whether or not central sensitisation and its accompanying spreading 
hyperalgesia have progressed to a stage where they are autonomous and no longer 
dependent on ongoing nociceptive input is crucial for the choice of treatment approaches 
for chronic pain syndromes – and for the prediction of treatment outcomes. The 
identification of patients where central sensitisation has become autonomous is key, as in 
these patients techniques based on nociceptive deafferentation, e.g. opioids or nerve 
blocking techniques – are unlikely to be effective, and techniques targeting central pain 
processing are indicated. Our research is the first to identify this phenomenon as a 
mechanism present in therapeutic non-responders and further underlines the central role of 
QST for hyperalgesia diagnosis and monitoring. Clearly, further research is necessary in this 
area. 
 
5.4. Summary: SATAPP.QST and Chronic Pain 
In summary, my research into altered pain processing using NASQ in chronic pain patients 
has identified spreading, heterotopic hyperalgesia, particularly of deep tissues, as a constant 
and characteristic feature of chronic pain. Its presence suggests that the body has not 
succeeded in restricting central sensitisation due to ongoing nociceptive inputs to the spinal 
cord, and that central sensitisation may have progressed rostrally up the neuraxis to include 
supraspinal structures. Such deep tissue hyperalgesia appears to occur irrespective of the 
type of chronic pain syndrome under consideration, and to become visible early on in 
development, i.e. within months of start of pain. Thus we would suggest that the presence of 
spreading deep tissue hyperalgesia be considered a basic criterion for the diagnosis of 
established chronic pain syndrome. 
 
5.4.1. Relevance for Clinical Use 
To my knowledge, this is the first time hyperalgesia characteristics of chronic pain have been 
investigated systematically. Based on my research, the following conclusions can be drawn: 
Firstly, hyperalgesia spread in chronic pain is typically heterotopic, and can be somato-
somatic, viscero-somatic and viscero-visceral. There is considerable inter-individual variation 
of onset/vulnerability to hyperalgesia and its spread, only individually diagnosable using QST. 
Secondly, hyperalgesia spread is associated with clinical progression of chronic pain. 
Differences in characteristics of hyperalgesia spread may be associated with differences in 
disease subtype, e.g. warm vs. cold CRPS I. This underlines the diagnostic, prognostic and 
therapeutic relevance of monitoring of hyperalgesia spread using QST. 
Thirdly, there are significant differences associated with gender in basal pain sensitivity, the 
dynamics of hyperalgesia development and response of hyperalgesia to treatment in the 
context of chronic pain disorders. These differences are only visible using QST. 
Fourthly, central sensitisation manifest as spreading hyperalgesia can become independent 
of peripheral nociceptive inputs, and thus no longer respond to treatments based on 
peripheral deafferentation such as nerve blocks or opioids. We are the first to formally 
documented this phenomenon. It has important therapeutic implications, i.e. the targeted 
use of drugs acting on central sensitisation, and can only be diagnosed/monitored using QST. 
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Fifthly, correlations between clinical pain measures and QST measures of hyperalgesia were 
either absent or variable. QST and clinical pain measures thus provide different but 
complementary information. For chronic as for perioperative pain, QST is needed to 
diagnose presence/spread of hyperalgesia as a sign of rostral spread of central sensitisation. 
Sixthly, spreading hyperalgesia as a manifestation of central sensitisation can be inhibited by 
specific treatments, such as the NMDA receptor antagonist ketamine. These therapeutic 
effects can only be documented and monitored using QST techniques. 
Finally, implementation of these conclusions in clinical chronic pain practice is impossible 
without implementing QST diagnostics. Our QST research has not only shown the usefulness 
of NASQ in clinical chronic pain practice, it has also proven the practicability of SATAPP.QST. 
 
5.4.2. Clinical Implementation 
Our conclusions above show that clinical implementation of SATAPP.QST requires QST 
diagnostics, validated and implemented in the NASQ paradigm with the following features: 
 multimodal test stimulation, electrical and mechanical stimulation are sensitive to 
secondary hyperalgesia/central sensitisation; electric skin stimulation is sensitive to 
inhibitory modulation, and pressure algometry detects deep tissue hyperalgesia. 
 multi-site test stimulation, to detect and define spreading hyperalgesia. As a 
minimum, sites close to/distant from the painful area should be tested. 
 test stimulation repeated in time, to document the time course of altered pain 
processing and its relation to chronic pain development and progression. 
 static and dynamic QST paradigms. Static QST tests passive basal pain sensitivity (e.g. 
hyperalgesia); dynamic QST uses conditioning painful stimulation to test how the 
body actively modulates nociceptive input (e.g. CPM/DNIC paradigm). 
My recommendations for the clinical implementation using NASQ for SATAPP.QST in the 
management of chronic pain disorders are summarised in the diagramme below (figure 22). 
 
Figure 22: SATAPP.QST in chronic pain disorders. PPT=pressure pain threshold, ePDT=electric pain detection 
threshold, ePTT=electric pain tolerance threshold, CPM=conditioned pain modulation paradigm, DNIC=diffuse 
noxious inhibitory controls, NRI=noradrenaline reuptake inhibitor. 
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6. SATAPP.QST for Pain Medicine: Conclusions 
6.1. NASQ: The Basis for SATAPP.QST for Pain Medicine 
My research has shown spreading, heterotopic hyperalgesia, likely an expression of rostrally 
spreading central sensitisation, to be the key alteration in pain processing associated with 
chronic pain and its development. This phenomenon is linked to pro-nociceptive shifts in 
endogenous (descending) pain modulation. Based on the Nijmegen-Aalborg Screening QST 
(NASQ) paradigm we developed, I have demonstrated the feasibility and usefulness of using 
quantitative sensory testing (QST) to diagnose and monitor characteristic changes in pain 
processing accompanying development, progression and presence of chronic pain. This 
demonstration makes implementation of a systematic approach to altered pain processing in 
clinical practice feasible – and urgently desirable. My work has shown this paradigm shift to 
be attainable for both perioperative and chronic pain practice. 
 
My research has defined a QST paradigm (the Nijmegen-Aalborg Screening QST, NASQ) 
suitable for a systematic approach to altered pain processing (SATAPP.QST). The NASQ 
paradigm includes at least two measurement points (close to/distant from painful site), two 
stimulation modalities (electric and pressure stimulation) and a CPM paradigm (cold pressor 
task as conditioning stimulation). It is well-accepted by all patients and can be completed in 
about 30 minutes. The NASQ-based research presented does not cover specific QST 
diagnostics for neuropathic pain, where thermal QST appears particularly useful for the 
diagnosis of peripheral nerve damage 67,68,194. My systematic approach to managing chronic 
pain and its development (figure 23, below) as the basis for effective prognosis, diagnosis, 
prevention and treatment of pain disorders, is summarised below (figure 23). 
 
 
 
Figure 23: Schematic for a systematic approach to altered pain processing (SATAPP.QST) using QST (NASQ) for 
pain medicine. Autonomy means that alterations in central pain processing (e.g. central sensitisation) have 
become independent of peripheral nociceptive drive. Mech=mechanical, heterot=heterotopic, 
CPM=conditioned pain modulation, DI=descending inhibition, TCA=tricyclic antidepressants, NRI=noradrenaline 
reuptake inhibitors 
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6.2. SATAPP.QST and Perioperative Pain 
In the perioperative context, I have for the first time been able to demonstrate that poorer 
preoperative endogenous pain modulation is associated with a greater risk of persistence 
and spread of postoperative hyperalgesia as well as a greater chance of having chronic pain 
six months after surgery. We further showed that patients ultimately reporting chronic pain 
at six months after surgery show a characteristic pattern of postoperative persistence and 
spread of heterotopic hyperalgesia. Such postoperative hyperalgesia is sensitive to both 
antinociceptive (nerve block, opioids) and antihyperalgesic (ketamine) interventions. These 
perioperative insights were gained using our simple NASQ paradigm lasting maximally 30 
minutes, involving at least two measurement sites (close to and distant from surgery), two 
types of stimulation (electric, pressure) and a CPM paradigm involving cold pressor task. 
 
Our results suggest the usefulness and feasibility of perioperative QST monitoring using 
NASQ for achieving a rational and effective systematic approach to altered pain processing in 
the context of 1) preoperative assessment for risk of chronic pain after surgery, 2) 
postoperative monitoring for early signs of chronic pain development, and 3) monitoring of 
effectiveness of perioperative management regarding chronic pain prevention and 
treatment. SATAPP.QST based on NASQ brings with it the realistic promise of significant 
improvements in surgical pain outcomes. Furthermore, it should also provide the basis for 
making perioperative pain management tangibly more effective – and resource-efficient – in 
the foreseeable future. 
 
6.3. SATAPP.QST and Chronic Pain 
For chronic pain patients, I have shown that spreading hyperalgesia made visible using NASQ 
is ubiquitous to a variety of chronic pain syndromes at various stages of progression. I was 
for the first able to systematically establish how the characteristics of spreading hyperalgesia 
are influenced by disease progression, disease subtype and gender, making these 
characteristics useful for process-oriented approaches to disease diagnosis and prognosis as 
well as for determining indications for specific disease treatments. In particular, we were 
able to demonstrate that specific treatment for central sensitisation (e.g. ketamine) 
inhibited its manifestation as hyperalgesia, and that this effect could be monitored using our 
NASQ paradigm. Furthermore, I was for the first time able to specifically demonstrate that in 
certain chronic pain patients, central changes in pain processing have become autonomous, 
i.e. independent of peripheral nociceptive drive. These findings are crucial because they 
carry the message that in certain chronic pain patients, nociceptive deafferentation (e.g. 
nerve blocks, opioids) will be therapeutically ineffective – and that treatment targeting 
altered central processing is the key to successful management. 
 
Again these insights regarding chronic pain were gained using our simple NASQ paradigm. 
Not lasting more than 30 minutes, the NASQ paradigm involves several measurement sites 
at variable distances from pain to determine hyperalgesia topography, at least two types of 
stimulation (electric, pressure) and a CPM paradigm involving cold pressor task. Our findings 
confirm the usefulness and feasibility of SATAPP.QST using NASQ for chronic pain 
management. This ap proach forms the basis of rational and effective systematic approaches 
to altered pain processing as the basis for 1) diagnosis and prognosis of chronic pain, 
including subtype definition, 2) monitoring for signs of chronic pain progression, 3) making a 
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rational choice of treatment option with a view to maximising treatment response, and 4) 
ongoing monitoring of effectiveness of chronic pain treatment and management. 
 
Consequently applied to the clinical practice of chronic pain, introduction of SATAPP.QST 
and NASQ should not only make the diagnostics of chronic pain much more effective and 
reliable, it also carries the potential to greatly reduce the cost and burden of chronic pain 
treatment by making achievement of therapeutic response more rapid and predictable in 
the individual patient. 
 
6.4. Implementing SATAPP.QST: Aim of the Present Review 
The present review provides not only the initial basis, but also the much-needed impetus for 
the urgently necessary paradigm shift in pain medicine away from symptom-based 
management towards a systematic approach to altered pain processing in pain diseases. To 
this end, we have now provided data substantiating three central concepts, namely: 
 
1) Quantitative sensory testing to make visible altered pain processing, implemented via 
the simple NASQ paradigm, represents a valid diagnostic method suitable for 
achieving SATAPP in routine clinical practice; 
2) Implementation of SATAPP by applying NASQ provides real clinical benefit in the 
diagnostics, prognostics and monitoring of chronic pain disorders and their 
progression; and 
3) First evidence is now available that pain management paradigms based on SATAPP 
and NASQ are therapeutically feasible and successful when applied in everyday 
clinical practice. 
 
Based on the research I have done over the last fifteen years, we have now provided a first 
foundation for the implementation of systematic approach to altered pain processing in 
everyday clinical pain practice in the very near future. Taken together, the three statements 
listed above demonstrate not only the feasibility, but also the necessity of now urgently 
addressing the task of implementing a systematic approach to altered pain processing 
(SATAPP.QST) to achieve long-awaited and necessary improvement in everyday clinical 
practice of pain diagnostics and therapeutics. 
 
6.5. SATAPP.QST: Future Perspectives 
Based on our development of a standardised and validated clinical approach (SATAPP.QST), 
large-scale clinical studies defining the presence and pattern of altered pain processing in 
groups of patients suffering from defined chronic pain syndromes using standardised 
diagnostics (NASQ) are the next necessary step. These studies should investigate not only 
hyperalgesia and its characteristics, but also the nature and effectiveness of the inhibitory 
responses mounted by the body. In order to be able to diagnose hyperalgesia and pro-
nociceptive shifts in pain modulation, normal subjects should be studied to generate normal 
values for pain processing. The large-scale nature of these studies is necessary due to the 
large variability in the nervous system response to ongoing nociceptive input regarding both 
sensitisation and subsequent modulation. 
 
Apart from the characterisation of the role of generalised hyperalgesia in chronic pain, other 
allied topics also need investigating, including how hyperalgesia develops and changes over 
time as the pain disease progresses, the question of if and when supraspinal central 
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sensitisation becomes independent from ongoing nociceptive input, and the impact of 
gender on the pain processing and inhibition in chronic pain. At a later stage, these studies 
need to include systematic study of therapeutic interventions, defining their effects on pain 
processing in health and disease using NASQ, as the basis for developing rational approaches 
to chronic pain management systematically targeting altered pain processing. Furthermore, 
it would be useful to be able to develop further QST parameters predictive of ultimate 
disease outcome and treatment response of chronic pain disorders, to permit targeting of 
medical resources at patients with greatest risk of poor outcomes. 
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7. Executive Summary 
Pain persisting beyond tissue healing after trauma and ensuing chronic pain syndromes 
continue to have a major personal and societal medical impact. Despite intense and 
concerted efforts in the last decades at achieving effective management through scientific 
and organisational advances, little real impression has been made by present symptom-
based therapeutic approaches on the prevention and treatment of chronic pain. Thus 
chronic pain and its development is a common, clinically relevant problem in urgent need of 
innovative, alternative management approaches targeting underlying mechanisms.  
 
Regarding mechanisms, the central discovery in pain research over the last quarter century 
is that noxious input results in altered pain processing, particularly central, and that such 
alterations are also seen in the context of developing and established chronic pain. It thus 
appears logical to conclude that making altered pain processing visible in patients in the 
clinical context – and then targeting these alterations therapeutically – may be key in 
achieving effective mechanism-orientated management of the hitherto intractable problem 
of chronic pain and its development. 
 
The work presented here is the result of almost two decades of clinical research using 
quantitative sensory testing (QST), an accepted – but hitherto mainly experimental – tool for 
revealing altered somatosensory processing. The outcome of my research programme is a 
new, systematic, mechanism-orientated approach for the successful management of chronic 
pain and its genesis in everyday clinical practice. 
 
The first major thrust of my research programme was to set up and validate a screening QST 
paradigm, the Nijmegen-Aalborg Screening QST (NASQ) paradigm, designed for systematic 
diagnosis of altered central pain processing in clinical pain patients. The main characteristics 
of the NASQ paradigm are as follows:  
 it is suitable and validated for use in clinical pain patients, lasting about 30 minutes 
 it reveals the topography of altered pain processing via skin and deep tissue stimuli 
 it contains both static (pain sensitivity) and dynamic (pain modulation) elements 
 it diagnoses central sensitisation and pro-nociceptive shifts in pain modulation 
 
The second major thrust of my research was to systematically implement and validate NASQ 
in clinical pain practice. This I did by developing a Systematic Approach To Altered Pain 
Processing using QST (SATAPP.QST) as the basis for a paradigm shift towards mechanism-
orientated approaches to pain disease diagnosis and treatment. SATAPP.QST provides this 
basis by answering four key questions about altered pain processing in pain disorders:  
 What is the source of nociception? 
 Is nociceptive transmission altered?  
 Is central pain processing altered?  
 Is altered central processing dependent on peripheral nociceptive drive? 
 
The first area to which I applied SATAPP.QST was in perioperative patients. Pain is a major 
negative outcome after surgery; its prevention and treatment represents a major clinical 
challenge. Using NASQ I have achieved the first systematic documentation of altered 
perioperative pain processing by measuring pain sensitivity at multiple sites, for skin and 
muscle, preoperatively and short-term (first week) and long-term (for six months) after 
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surgery. I also measured descending pain modulation via conditioned pain modulation (CPM) 
paradigm using a cold pressor task.  
 
The perioperative application of NASQ has permitted me to provide the first and only 
comprehensive description available to date of neuroplasticity after surgery and the factors 
influencing it. The first week after surgery, after an initial 24 hour inhibitory phase, 
augmented pain sensitivity becomes increasingly manifest. This hyperalgesia spreads rapidly 
away from the site of surgery and is more pronounced in the absence of adequate analgesia 
during surgery and in vulnerable patients (i.e. preoperative pain, nerve damage). Patients 
reporting chronic pain six months after surgery consistently manifest more spreading 
hyperalgesia throughout the preceding six months, both of skin and muscle. Greater 
vulnerability to spreading hyperalgesia – and to chronic pain – correlates with weaker 
preoperative descending inhibitory pain modulation.  
 
Chronic pain development after surgery is thus associated with persistence and rostral 
spread of neuraxial central sensitisation, a process facilitated by preoperative pro-
nociceptive shifts in descending pain modulation. SATAPP.QST for the first time makes it 
possible to achieve rational and effective perioperative pain management by enabling: 1) 
preoperative assessment for risk of chronic pain after surgery, 2) postoperative monitoring 
for early signs of chronic pain development, and 3) monitoring of effectiveness of 
perioperative management regarding chronic pain prevention and treatment. 
 
The second area in which I investigated SATAPP.QST was in the diagnosis and management 
of four intractable chronic pain conditions of different aetiologies. Using the NASQ paradigm 
we studied patients with 1) complex regional pain syndrome (CRPS) type I 
(neuroinflammatory pain), 2) chronic low back pain (somatic and neuropathic pain), 3) 
chronic pancreatitis (viscero-somatic pain), and 4) dysmenorrhoea (viscero-visceral pain). My 
key finding was that chronic pain disorders are consistently linked to spreading, heterotopic 
deep tissue hyperalgesia – regardless of the original diagnosis. This ground-breaking finding 
is congruent with my studies on pain persistence after surgery, and indicates that persistent, 
rostrally spreading central sensitisation is key to chronic pain and its development.  
 
Clinical application of NASQ has resulted in pioneering conclusions central to achieving 
SATAPP.QST-based management of chronic pain. The first-ever clinical implementation of 
such an approach by my group has revolutionised our own pain practice. The innovative 
findings resulting from my research on chronic pain may be summarised as follows:  
 Spreading, heterotopic deep tissue hyperalgesia is diagnostic for chronic pain, 
 Hyperalgesia spread differs with disease subtype, and is linked to pain progression, 
 Central sensitisation manifest as spreading hyperalgesia can become independent of 
peripheral nociceptive inputs, thus no longer responding to peripheral deafferentation 
treatments, e.g. nerve blocks, opioids, 
 Specific targeted treatments, e.g. the NMDA antagonist S-ketamine, are necessary to 
inhibit central sensitisation manifest as spreading hyperalgesia, 
 Clinical pain measures and QST measures correlate poorly, thus QST and clinical pain 
measures yield different but complementary information. 
 
Application of SATAPP.QST in clinical chronic pain practice thus permits a key paradigm shift 
towards mechanism-orientated management by enabling: 1) diagnosis and prognosis of 
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chronic pain, including subtype definition, 2) monitoring for signs of chronic pain 
progression, 3) rational treatment choices for maximal treatment response, and 4) ongoing 
monitoring of effectiveness of chronic pain management. 
 
In conclusion, altered central pain processing is key to understanding the mechanisms of 
chronic pain and its genesis. QST methods are necessary to reliably diagnose alterations in 
pain processing. My research programme for the first time provides a comprehensive and 
practical basis for the urgently needed paradigm shift in pain medicine away from symptom-
based management towards a mechanism-orientated approach to altered pain processing. 
This shift can be implemented in clinical practice now, based on the systematic framework 
(SATAPP.QST) and accompanying tools (NASQ) validated by my research. My studies show 
that NASQ makes visible altered pain processing and represents a valid clinical diagnostic 
method, and that SATAPP.QST implementation provides real clinical benefit in the 
diagnostics, prognostics and monitoring of chronic pain disorders and their progression. 
Furthermore, we provide first evidence that pain management paradigms based on 
SATAPP.QST are feasible and successful when implemented in clinical practice. 
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8. Danish Summary (Sammenfatning) 
Vedvarende smerter efter heling af væv, som har været udsat for traume, samt 
efterfølgende kroniske smertesyndromer har store personlige og samfundsmæssige 
omkostninger. På trods af de seneste årtiers intense og koordinerede indsats for at opnå 
effektiv behandling ved hjælp af videnskabelige og organisatoriske fremskridt er der kun 
fremkommet små reelle forbedringer med den nuværende symptombaserede terapeutiske 
tilgang til imødegåelse og behandling af kroniske smerter. Kroniske smerter og udviklingen 
heraf er derfor stadig et stort klinisk relevant problem, som kræver innovative og alternative 
behandlingstilgange, som målrettes mod de underliggende mekanismer.  
 
Med hensyn til mekanismerne er den centrale opdagelse inden for smerteforskningen i de 
seneste 25 år, at giftige input resulterer i ændret smertebearbejdning, især centralt, og at 
sådanne ændringer også ses i sammenhæng med udvikling og etablering af kronisk smerte. 
Det synes derfor logisk at konkludere, at en tydeliggørelse af den ændrede 
smertebearbejdning hos patienter i klinisk sammenhæng – efterfulgt af en målrettet 
terapeutisk indsats mod disse ændringer – kan være nøglen til at opnå en effektiv 
mekanismeorienteret håndtering af det hidtil intraktable problem med kroniske smerter og 
deres udvikling.  
 
Det arbejde, som præsenteres her, er resultatet af næsten to årtiers klinisk forskning ved 
hjælp af kvantitative sensoriske tests (QST), som er et anerkendt – men hidtil mest 
eksperimentelt anvendt – værktøj til påvisning af ændret somatosensorisk bearbejdelse. 
Resultatet af mit forskningsprogram er en ny, systematisk mekanisme-orienteret tilgang, 
som sikrer succesfuld behandling af kronisk smerte i klinisk praksis samt viden om, hvorfor 
smerten opstår.  
 
Den første betydelige del af mit forskningsprogram bestod i at opsætte og validere et 
screenings-QST paradigme (The Nijmegen-Aalborg Screening QST (NASQ) Paradigm) for 
systematisk diagnosticering af ændret central smertebearbejdning hos kliniske 
smertepatienter. NASQ-paradigmet kendes på følgende: 
 det er velegnet og valideret til brug på kliniske patienter (varighed ca. 30 minutter) 
 det afdækker topografien af ændret smertebearbejdning ved hjælp af stimuli på hud 
og i dybe væv 
 det indeholder både statiske (smertefølsomhed) og dynamiske (smertemodulation) 
elementer 
 det diagnosticerer central sensibilisering og pro-nociceptive ændringer i 
smertemodulationen 
 
Den anden store del af mit forskningsprogram bestod i en systematisk implementering og 
validering af NASQ i klinisk praksis. Til dette formål udviklede jeg metoden ”en systematisk 
tilgang til ændret smertebearbejdning ved hjælp af QST” (A Systematic Approach To Altered 
Pain Processing using QST (SATAPP.QST)) som grundlag for et paradigmeskifte mod mere 
mekanisme-orienterede tilgange til diagnosticering og behandling af smertelidelser. 
SATAPP.QST danner grundlag for besvarelse af fire hovedspørgsmål om den ændrede 
smertebearbejdning hos patienter med smertelidelser:   
 Hvad er kilden til nociception? 
 Ændres den nociceptive transmission? 
 Ændres den centrale smertebearbejdning? 
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 Er ændret central bearbejdning afhængig a perifert nociceptiv drive? 
 
Den første gruppe, hvorpå SATAPP.QST blev anvendt, var perioperative patienter. Smerter er 
et væsentligt negativt resultat af operationer; forhindring og behandling af smerter udgør 
derfor en stor klinisk udfordring. Ved hjælp af NASQ har jeg opnået den første systematiske 
dokumentation af ændret perioperativ smertebearbejdning ved at måle smertefølsomheden 
flere steder (på hud og i muskler) før operation, kort efter (efter en uge) og lang tid efter 
operation (efter seks måneder). Jeg målte også den descenderende smertemodulation ved 
hjælp af et paradigme for konditioneret smertemodulation (CPM) indeholdende en kold 
pressor test.  
 
Den perioperative anvendelse af NASQ har gjort det muligt for mig at udarbejde den første, 
hidtil eneste og mest omfattende beskrivelse af neuroplasticitet efter operation samt de 
faktorer, der påvirker denne. Den første uge efter operationen, efter en indledende 24-
timers hæmmende fase, manifesteres en forstærket smertefølsomhed. Denne hyperalgesi 
spredes hurtigt væk fra operationsstedet og bliver mere udtalt i tilfælde med utilstrækkelig 
bedøvelse under operationen og hos sårbare patienter (dvs. patienter med præoperative 
smerter eller med nerveskader). Patienter, der rapporterer om kroniske smerter et halvt år 
efter en operation, udviser konsekvent mere spredt hyperalgesi i de seks måneder både i 
hud og muskler. Større sårbarhed over for udbredt hyperalgesi – og over for kronisk smerte 
– korrelerer med svagere præoperativ descenderende hæmmende smertemodulation. 
 
Udvikling af kronisk smerte efter operation forbindes derfor med vedholdenhed og rostral 
spredning af neuraxial central sensibilisering; en proces, som faciliteres af præoperative pro-
nociceptive ændringer i den descenderende smertemodulation. SATAPP.QST gør det for 
første gang muligt at udføre en rationel og effektiv perioperativ smertehåndtering ved hjælp 
af: 1) en præoperativ vurdering af risikoen for kronisk smerte efter operation, 2) en 
postoperativ monitorering af tidlige tegn på udvikling af kronisk smerte og 3) monitorering af 
effektiviteten af den perioperative håndtering med hensyn til opståen og behandling af 
kronisk smerte.  
 
dDet andet område, hvor jeg undersøgte SATAPP.QST, var i forbindelse med diagnose og 
behandling af fire intraktable kroniske smertelidelser med forskellig ætiologi. Ved hjælp af 
NASQ-paradigmet undersøgte vi patienter med 1) komplekst regionalt smertesyndrom 
(CRPS) type 1 (neuro-inflammatorisk smerte), 2) kroniske lændesmerter (somatisk og 
neuropatisk smerte), 3) kronisk pankreatitis (viscero-somatisk smerte) og 4) dysmenoré 
(viscero-visceral smerte). Det vigtigste resultat var, at kroniske smertelidelser konsekvent er 
forbundet med spredt heterotopisk hyperalgesi i dybt væv – uanset hvilken diagnose, der 
oprindeligt var stillet. Dette banebrydende resultat er i overensstemmelse med mine studier 
i vedvarende smerter efter operation og indikerer, at vedvarende rostral spredt central 
sensibilisering er nøglen til kronisk smerte og udviklingen heraf. 
 
Den kliniske anvendelse af NASQ har resulteret i banebrydende konklusioner, som er 
centrale for at kunne udføre en SATAPP.QST-baseret håndtering af kronisk smerte. Min 
forskningsgruppe har som de første implementeret denne fremgangsmåde, hvilket har 
revolutioneret vores smertepraksis. De nyskabende resultater af min forskning i kronisk 
smerte kan opsummeres som følger: 
 Spredt heterotopisk hyperalgesi i dybt væv er diagnosen for kronisk smerte 
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 Spredningen af hyperalgesi varierer afhængig af lidelsens type og er forbundet med 
smerteudvikling 
 Central sensibilisering - manifesteret som spredt hyperalgesi - kan blive uafhængig af 
perifere nociceptive input og reagerer således ikke længere på perifere 
deafferentationsbehandlinger, f.eks. nerveblokader og opioider 
 Specifikke målrettede behandlinger, f.eks. NMDA antagonist S-ketamin, er 
nødvendige for at inhibere central sensibilisering manifesteret som spredt hyperalgesi 
 Kliniske smertemål og QST-målinger korrelerer dårligt, således at QST og kliniske 
smertemålinger giver forskellig men komplementær information  
 
Anvendelse af SATAPP.QST i klinisk praksis på kroniske smerter tillader således et 
paradigmeskifte mod en mere mekanisme-orienteret behandling, som gør det muligt, 1) at 
diagnosticere og opstille en prognose for kronisk smerte inklusive definition af undertype, 2) 
at monitorere tegn på udvikling af kronisk smerte, 3) at træffe rationelle behandlingsvalg for 
opnåelse af det bedst mulige behandlingsrespons og 4) at udføre løbende monitorering af 
effektiviteten af håndteringen af den kroniske smerte.  
 
Afslutningsvis skal det nævnes, at ændret central smertebearbejdning er nøglen til at forstå 
mekanismerne i kronisk smerte og dens opståen. QST-metoderne er nødvendige for at 
kunne stille en sikker diagnose vedrørende ændringer i smertebearbejdningen. Min 
forskning har skabt det første omfattende og praktiske grundlag for et presserende 
paradigmeskifte inden for smertemedicin; væk fra den symptombaserede behandling og 
mod en mekanismeorienteret tilgang til den ændrede smertebearbejdning. Det er nu muligt 
at implementere skiftet i klinisk praksis baseret på det systematiske grundlag (SATAPP.QST) 
med det tilhørende værktøj (NASQ), som min forskning har valideret. Mine studier viser, at 
NASQ synliggør en ændret smertebearbejdning og repræsenterer en valid klinisk 
diagnosticeringsmetode samt at implementering af SATAPP.QST giver reelle kliniske fordele 
inden for diagnosticering, prognostik og monitorering af kroniske smertelidelser og deres 
udvikling. Endvidere har vi fremlagt de første beviser på, at smertehåndteringsparadigmer 
baseret på SATAPP.QST er praktiserbare og succesfulde, når de implementeres i klinisk 
praksis.  
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